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ABSTRACT 
 
Reversible acetylation regulated by histone acetyltransferases (HATs) and 
histone deacetylases (HDACs) plays a major role in transcriptional regulation. 
HATs promote transcriptional activation by adding acetyl groups to the histone 
tails, while HDACs act in the reverse process leading to transcriptional 
repression. In addition to histones, HATs and HDACs also modify numerous 
proteins, and therefore affect many biological processes. The HDAC family 
consists of 18 members, which are grouped into four classes, namely I, II, III and 
IV, with class II further subdivided into subclass IIa and IIb. HDAC6 is a 
predominantly localized cytoplasmic deacetylase, which belongs to class IIb. 
HDAC6 is unique among the HDAC family members in that it expresses two 
complete functional deacetylase domains, a cytoplasmic anchoring motif, and an 
ubiquitin binding domain. Like many other HDACs, HDAC6 has a growing list of 
substrates. HDAC6 is known for its deacetylase activity towards cytoplasmic 
proteins α-tubulin and cortactin, a function that is known to promote HDAC6-
mediated cell migration. HDAC6 is also regulated by post translational 
modifications such as, phosphorylation, acetylation and ubiquitination. Using 
mass spectrometric analysis, we have identified additional phosphorylation sites, 
Threonine-1031 and Serine-1035, within the C-terminal of HDAC6. Both sites are 
located within an extracellular signal regulated kinase (ERK) recognition motif, 
vii 
 
while Serine-1035 is a major site targeted by ERK. Previous studies have 
identified ERK as a pivotal player in promoting tumorgenesis. HDAC6 was 
identified as a major player in promoting cell migration, and was also shown to be 
required for efficient oncogenic tumorigenesis. However, whether ERK can 
regulate HDAC6 to promote cell migration have not been investigated. Based on 
published data and our preliminary results, we hypothesized that 1) Serine-1035 
of HDAC6 is a major phosphorylation site of HDAC6 that plays a critical role in 
promoting HDAC6-mediated cell migration by affecting deacetylation of its 
substrates; and 2) HDAC6 promotes cell migration in vivo.  Using in vitro and in 
vivo studies, we confirmed that Serine-1035 of HDAC6 is phosphorylated by 
ERK1. In addition, we found that activation of the ERK-mitogen activated protein 
kinase (MAPK) signaling axis promotes HDAC6 phosphorylation. By using 
unphosphorylation mimicking mutants of HDAC6 Serine-1035 site, we observed 
that unphosphorylation of HDAC6 at this site does not affect HDAC6 enzymatic 
activity towards histones or cortactin. However, unphosphorylation of HDAC6 at 
Serine-1035 hinders HDAC6’s ability to deacetylate α-tubulin and β-catenin. 
Importantly, hypo-phosphorylation of HDAC6 at this site significantly attenuates 
its ability to promote cell migration using the cell lines model. We showed for the 
first time that HDAC6 also promotes metastasis in vivo using a mouse model. In 
conclusion, this study identified HDAC6 Serine-1035 as a novel phosphorylation 
site which can be phosphorylated by ERK1, and this phosphorylation status of 
HDAC6 can promote cell migration. Since the ERK-MAPK pathway is a major 
viii 
 
target of numerous signaling events, inhibitors of both ERK and HDAC6 may 
prove beneficial for future research directions. 
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CHAPTER ONE 
INTRODUCTION 
An Overview of Histones 
 The core histone molecule is evolutionarily conserved and is formed by 
histones H2A, H2B, H3 and H4 (1). The nucleosome is the repeating unit of 
chromatin. These units are formed by approximately 145-147 base pairs of DNA 
wrapped around a histone octamer, that consists of an H3-H4 tetramer and two 
H2A-H2B dimers (1). The N-terminal tails of the histones are very flexible, and 
therefore, are involved in neighboring nucleosome interaction and nuclear factor 
interactions (1). The N-terminal tail of the histones can also be covalently 
modified through reversible post-translational modifications such as lysine 
acetylation, lysine and arginine methylation, serine and threonine 
phosphorylation, ADP-ribosylation, ubiquitination, and sumoylation (2). Histone 
acetylation is one of the most understood modifications, that occurs on the ε-
amino group of evolutionarily conserved lysine residues (3). Histone 
acetyltransferases (HATs) and histone deacetylases (HDACs) act in a reversible 
manner to either add or remove an acetyl group on the histone tail, respectively 
(4). These modifications affect chromatin conformation and lead to either 
transcriptional activation (hyperacetylated histones) in the case of HATs or 
transcriptional repression (hypoacetylated histones) in the case of HDACs (4, 5). 
2 
 
An Overview of Histone Deacetylases 
 Eighteen HDACs are grouped into four classes (I, II, III and IV) according 
to their size and structure (6). Class I HDACs are ubiquitously expressed and 
consist of HDACs 1,2,3 and 8. Class I HDACs are closely related to the yeast 
(saccharomyces cerevisiae) transcriptional regulator, reduced potassium 
deficiency 3 (RPD3) (3). Two class I HDACs (1 and 2) were identified as 
components of multiprotein complexes such as Sin3/HDAC and NuRD/Mi2/NRD 
(7). Class II HDACs are divided into two subclasses, class IIa and class IIb. 
Class IIa consists of HDACs 4, 5, 7, and 9, whereas class IIb consists of HDAC6 
and 10. Class II HDACs show a tissue specific pattern of expression. They also 
share similar domains with another deacetylase found in yeast, HDA1 (3, 5). 
Class III HDACs consist of 7 sirtuins (silent information regulator 2 (sir2)-related 
protein) SIRT 1-7 (8). Class IV only consists of one member, HDAC11. HDAC11 
contains conserved residues within its catalytic core region that are shared by 
both class I and class II HDACs (9).  
 HDACs are not known to bind directly to DNA, but they are recruited to 
specific promotes because of their interaction with DNA sequence specific 
transcription factors (5). HDACs consist of nuclear localization signals (NLS) that 
allow HDACs to reside in the nucleus. However additional regulatory domains 
may influence the cytoplasmic localization of many HDACs (10). Class I HDACs 
are found mostly in the nucleus, in particular, HDAC1 and HDAC2, because of 
the absence of a nuclear export signal (NES) (3). Class II HDACs display 
shuttling activity between the nucleus and cytoplasm in response to cellular 
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signals (3). In addition, class II HDACs interact with the chaperone protein 14-3-
3, that allows for nucleo-cytoplasmic shuttling (5). Binding of 14-3-3 to the 
phosphorylated serine residues in the N-terminus of HDACs masks the nuclear 
import signal thus preventing them from entering the nucleus (5). The class IV 
HDAC, HDAC11, localizes to the nucleus but may also form a complex with 
HDAC6 in the cytoplasm (11).  
HDACs catalytic domains are formed by approximately 390 amino acids, 
consisting of some conserved amino acids. Crystal structures revealed an HDAC 
catalytic core consisting of a tubular pocket, a zinc binding site, and two 
asparagines and two histidines that form hydrogen bonds. This arrangement 
within the catalytic domain forms a charge relay system similar to the active sites 
of serine proteases. The residues within the active site are conserved across the 
HDAC family members (12). The Zn2+ ion is an essential component of the 
charge relay system. The wall of the pockets consists of hydrophobic and 
aromatic residues identical to that of HDAC1 (12). The class I, II and IV classic 
families require Zn2+ for deacetylase activity and share similarity in their 
sequences (8). On the other hand, class III HDACs do not display sequence 
similarity to the classic family of HDACs and require NAD+ as a cofactor (8).  
 
Acetylation of Non-Histone Proteins 
 Acetylation on lysine residues is a conserved post translational 
modification (PTM) from prokaryotes to humans (13, 14). Apart from histones, 
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numerous other proteins are also modified by acetylation.  Many of these 
acetylated proteins are involved in processes including RNA splicing, cell cycle, 
chromatin remodeling, protein phosphorylation, DNA damage and repair, 
cytoskeleton reorganization, and transcription (14, 15). HATs and HDACs are 
also subject to acetylation (14, 15). Many acetylated proteins are important 
factors in pathways that are implicated in cancer (13). In addition to cancer, 
acetylation and deacetylation processes have been linked to other disease 
states, such as neurodegeneration, cardiovascular disorder, inflammation, lung 
disease, and aging (16). In some cases non-histone proteins are deacetylated by 
more than one HDACs, as in the case for p53. The tumor suppressor p53 was 
the first identified non-histone HDAC substrate, and it can be deacetylated by 
both HDAC1 and SIRT1 (13). The cytoplasmic protein α-tubulin is also another 
such protein that can be deacetylated by both HDAC6 and SIRT2 (15). 
  
Phosphorylation of Histone Deacetylases 
 PTM of any protein has the ability to modulate the protein’s functions, its 
enzymatic activity, its subcellular localization, its stability, and its interactions with 
other binding partners (17). HDACs are strongly regulated by phosphorylation as 
well. HDAC1 is phosphorylated by casein kinase 2 (CK2) both in vitro and in vivo. 
Studies have shown that disrupting HDAC1 phosphorylation by CK2 results in 
diminished HDAC1 enzymatic activity and complex formation (18). Like HDAC1, 
HDAC2 is also phosphorylated by CK2. This modification is critical for HDAC2 
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complex formation with mSin3 and Mi2, and is also important for HDAC2 
enzymatic activity but not necessary for transcriptional repression (19). 
Phosphorylation of HDAC1 and HDAC2 disrupts HDAC1/2 complex formation, as 
well as the interactions of HDAC1 between corepressors mSin3A and YY1 (20). 
This may suggest that phosphorylation of HDAC1 and HDAC2 hinders 
transcriptional repression (20). HDAC3, another class I HDAC, can also be 
phosphorylated by CK2. This phosphorylation event is critical for HDAC3’s 
enzymatic activity (21). Dephosphorylation also affects the activity of HDAC3. 
The protein phosphatase PP4c dephosphorylates the same site (Serine 424) 
phosphorylated by CK2 on HDAC3. The phosphatase activity leading to 
dephosphorylation of HDAC3 resulted in reduced HDAC3 enzymatic activity (21). 
HDAC8 can be phosphorylated by protein kinase A (PKA) both in vitro and in 
vivo. Mutation of the phosphorylation site to mimic an unphosphorylated form 
enhances HDAC8 deacetylase activity, whereas enhanced phosphorylation by 
an activator, or by a phospho-mimetic, resulted in decreased enzymatic activity 
of HDAC8 and enhanced acetylation of histones H3 and H4, indicating the 
importance of PTM on histone acetylation status (22). 
 Class II HDACs are involved in nucleo-cytoplasmic shuttling, an event that 
is dependent on phosphorylation. HDAC4 is present in both the cytoplasm and 
the nucleus. HDAC4 was shown to be associated with extracellular signal 
regulated kinase (ERK1/2), leading to HDAC4 phosphorylation and increased 
localization in the nucleus (23). In addition to ERK1/2, HDAC4 can also be 
phosphorylated by calcium/calmodulin-dependent protein kinase IV (CaMKIV), 
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which can also affect HDAC4 subcellular localization by promoting HDAC4’s 
nuclear export (24). As such, phosphorylation of HDAC4 regulates its intracellular 
localization (23) 
PKA phosphorylates HDAC5 and was shown to prevent HDAC5’s nuclear 
export, further resulting in suppressed gene transcription (25). This 
phosphorylation event blocks the interaction between HDAC5 and the protein 
chaperon 14-3-3 involved in nuclear export (25). The nuclear export of HDAC7 is 
also mediated by 14-3-3. Both HDAC5 and HDAC7 subcellular localization can 
be controlled by CaMK1 and 14-3-3 (26). In addition, it was shown that PKC 
related kinase (PRK 1/2) interacts with HDAC5 mapped to its nuclear localization 
signal (27).  Altogether, these results indicate that more than one site within the 
HDACs structure can be phosphorylated by different kinases. 
 
Clinical Relevance of Histone Deacetylases 
Acetylation and deacetylation of histones affect numerous gene 
expression in processes implicated in cancer promotion, such as angiogenesis, 
cell adhesion, cell migration, cell invasion, and cell proliferation (10). In vitro 
model using HDAC inhibitors (HDACi) have also suggested that HDACs are 
involved in tumor development. It is thought that the use of HDACi leads to 
increase acetylation and increase recruitment of DNA binding transcription 
factors (TFs), which alters gene expression (3, 10). The use of HDACi may prove 
to be beneficial, because HDACi inhibits cell proliferation, promotes 
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differentiation and can also cause apoptotic induction (10). HDACs lead to 
transcriptional repression by removing the acetyl group from the histone tails 
resulting in a compact chromatin structure. This prevents the entry of TFs that 
are usually necessary for transcriptional promotion (10). Specifically, HDACi 
function by binding to the Zn2+ ions needed for HDACs catalytic functions (12). 
HDACi, therefore, de-represses the inhibitory function of HDACs. This is 
important because repressed genes are often tumor suppressors, such as cell 
cycle inhibitors, differentiation factors or inducers of apoptosis (10).  
HDACs are not just for histones, numerous non-histone proteins are being 
identified as HDACs substrates including TFs, chaperons, signaling mediators 
and DNA repair proteins only to name a few (28). Because HDACs are involved 
in numerous cancer progression processes, the use of HDACis in preclinical 
setting is becoming more apparent. In fact, HDACi are being investigated as a 
clinically relevant treatment option for cancer (29). HDACis are separated into 
four different groups that include the short chain fatty acids, hydroxamic acids, 
cyclic tetrapeptides, and benzamides (28). The HDACi, vorinostat 
(suberoylanilide hydroxamic acid (SAHA)), was the first one approved by the 
U.S. Food and Drug Administration (FDA) in 2006 for treatment of cutaneous T-
cell lymphoma (CTCL) in patients with progressive, persistent or recurrent 
disease (30). Treatments have shown positive results in lymphoid neoplasm, but 
have been less effective for solid malignancy. Side effects from this treatment 
option showed fatigue, weakness, diarrhea, and vomiting and minimal toxicity 
(30). SAHA is a pan-HDACi which can potently inhibit class I and class II HDACs, 
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resulting in effects such as cell cycle arrest in transform cells due to up-regulation 
of the cyclin-dependent kinase inhibitor, p21WAF1 (31). Experiments using this 
inhibitor showed increased acetylation of histone H3 and H4 in chromatin 
associated with the cyclin dependent kinase inhibitor, p21WAF1 gene, with 
subsequent increase in p21WAF1 expression in bladder transitional cell carcinoma 
cells (32). Other HDACi, such as depsipeptide also showed down regulation of 
cyclin D1 and upregulation of p21WAF1 leading to further G1 cell cycle arrest (33). 
In addition, HDACi in combination with other drugs, such as DNA methyl 
transferase inhibitors (DNMTi), is also being explored for the treatment of 
hematological malignancies, as well as for solid tumors (29, 34). Because 
HDACs not only affect the acetylation status of histones but also non-histone 
proteins, their activity in disease states, such as cancer, is becoming more 
widespread. Since HDACs are essential for many cellular functions, the above 
pan-HDAC inhibitors are usually toxic to the patients. It is important to 
understand the functions of individual HDAC, which may aid in the development 
of novel HDAC-specific inhibitors for cancer treatment.  
 
An Overview of Histone Deacetylase 6 
The class IIb HDAC6 is mainly a cytoplasmic protein (35, 36). However, in 
some instances, as in the case of arrest in cell proliferation, a fraction of mouse 
HDAC6 (mHDAC6) can be found in the nucleus (36). Human HDAC6 (hHDAC6) 
consists of one nuclear localization signal (NLS) and two nuclear export signals 
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(NES), double deacetylase domains, eight consecutive serine-glutamic acid 
containing tetradecapeptide (SE14) repeats, and a zinc-finger domain (Figure 1). 
Like other HDACs, localization of HDAC6 is controlled by its localization signals. 
hHDAC6 possesses two NES; one located in the N-terminus and the other in the 
C-terminus, and an N-terminus NLS (35). On the other hand, mHDAC6 
possesses three nuclear export signal-like motifs (36). HDAC6 is unique among 
the HDACs, in that it contains two catalytically functional domains that are 
arranged in tandem (3). This similarity is shared by the other class IIb HDAC 
member, HDAC10.(37). 
HDAC6 also possesses a zinc finger domain termed ubiquitin carboxyl-
terminal hydrolase like zinc finger (ZnF-UBP) within its C-terminal region (38). 
This feature of HDAC6 allows it to be associated with monoubiquitin and 
polyubiquitin (38-40). HDAC6 itself can be ubiquitinated both in vitro and in vivo, 
but HDAC6 is a relatively stable proteins in vivo (39). An SE14 repeat domain is 
also present within the C-terminus of hHDAC6, but is excluded from murine, 
C.elegans, and drosophila (35). Size exclusion chromatography using full length 
HDAC6, deletion of the zinc finger domain or both deletion of the zinc finger 
domain and SE14 motif, suggested that it is possible for the SE14 repeat domain 
to form an unusual structure and this in turn affects the overall structure of 
hHDAC6 (35). The cytoplasmic localization of hHDAC6 is also regulated through 
a different mechanism than that of mHDAC6. The SE14 motif found on hHDAC6 
may account for HDAC6 cytoplasmic retention (35). Furthermore, the multiple 
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motifs to ensure HDAC6’s presence in the cytoplasm, may suggest that 
evolutionary pressures reinforced HDAC6 localization in the cytoplasm (41).  
 
Post Translational Modification of HDAC6 
Acetylation of HDAC6 
PTM of HDAC6 affects its functions, localization and interactions with its 
substrates. It was previously shown that HDAC6 can be acetylated by the HAT, 
p300. Acetylation of HDAC6 negatively regulates HDAC6 deacetylase activity 
(42). Consistently, another study showed that acetylation of HDAC6 by p300 
decreases HDAC6 ability to deacetylate its cytoplasmic substrate, α-tubulin, 
which negatively affects its ability to promote cell motility (43). HDAC6 
localization to the nucleus is dependent on its interaction with importin α, an 
interaction that is hindered by acetylation. The localization of HDAC6 in the 
nucleus  promotes deacetylation of histones and other HDAC6 nuclear 
substrates. However, when HDAC6 is acetylated, HDAC6 is retained in the 
cytoplasm and deacetylation of histones are hindered (43).  
 
Phosphorylation of HDAC6 
 Like many of the other HDACs, HDAC6 can also be phosphorylated by 
different kinases. Glycogen synthase kinase 3β (GSK-3β) was shown to 
phosphorylate HDAC6 at its Serine 22 site located in the N-terminus. The 
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consensus phosphorylation site recognized by GSK-3β is also shared by kinases 
CdK5 and p38 MAPK (44). Inhibition of GSK-3β mediated phosphorylation of 
HDAC6 results in a decreased deacetylase activity in cytoplasmic extracts of 
hippocampal neurons, and increased α-tubulin acetylation (44). Aurora A is a 
centrosomal kinase that is involved in regulating mitotic entry. Aurora A was also 
shown to phosphorylate HDAC6, to promote its deacetylase activity towards its 
substrate α-tubulin and subsequently to promote cilia disassembly. However, 
Aurora A’s phosphorylation site is yet to be identified (45). HDAC6 C-terminal 
catalytic domain at residue tyrosine 570 can be phosphoryated as well. However, 
phosphorylation at this site negatively regulates HDAC6 catalytic activity, 
resulting in increased α-tubulin acetylation which influences epidermal growth 
factor receptor (EGFR) trafficking (46). Therefore, it appears that the location of 
the phosphorylation sites, as well as the kinases involved, determines how 
HDAC6 activity is regulated.  
 
Cytoplasmic Substrates of HDAC6 
 As a predominantly cytoplasmic deacetylase HDAC6 is involved in 
promoting many cellular functions including cell migration, lymphocytes 
chemotaxis, immune synapse formation, degradation of mis-folded proteins, and 
the clearance and regulation of glucocorticoid receptors (47). HDAC6 promotes 
its function through many of its substrates and interacting proteins. However, 
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some of the well known cytoplasmic substrates of HDAC6 are α-tubulin, 
cortactin, and HSP90 (48-50) 
 
α-Tubulin  
Microtubules (MT) are cytoskeletal polymers made up of α and β tubulin 
heterodimers found within all eukaryotic cells. They are involved in multiple 
biological processes, such as mitosis, cell motility, intracellular transport, 
secretion, cell shape maintenance, and cell polarization (51). Post translational 
modifications, such as acetylation, can affect the microtubule network, 
particularly, the α-subunit of tubulin (52). Lysine 40 of the α-subunit can be 
modified because of its position on the luminal surface of microtubules (52). 
HDAC6 was shown to be associated with the MT network and deacetylates α-
tubulin (48, 53). HDAC6 can deacetylate α-tubulin both in vitro and in vivo to 
regulate microtubule stability (53, 54). HDAC6 also colocalizes with the MT 
network, and inhibiting HDAC6 enzymatic activity using HDACi, as well as 
targeted inactivation resulted in hyperacetylation of the MT (53). HDAC6 is 
involved in regulating the stability of MTs, as overexpression of HDAC6 was 
observed with polymerized MTs, whereas HDAC6 knockdown expression 
increased MTs stability (55). There are conflicting data as to whether one or both 
HDAC6 deacetylase domains are required for its activity towards α-tubulin. 
Zhang et al., showed that both HDAC6 catalytic domains are required for 
deacetylation of tubulin. Mutation in one deacetylase domain of HDAC6 was 
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sufficient to eliminate its entire activity, this result suggests that the cooperation 
between the two domains are necessary for activity (53). In addition to the two 
required domains, the arrangement of the two domains is important as well. 
Altering the linker region between the two domains affects HDAC6 deacetylase 
activity towards histones and α-tubulin (56). Another group showed that HDAC6 
deacetylase activity towards α-tubulin is contained only in its C-terminal catalytic 
domain (57). The association of HDAC6 with the MT network and subsequent 
deacetylation of α-tubulin were shown to promote cell migration (48, 57). HDAC6 
is concentrated at high protrusive region, such as lamellipodium. HDAC6 
deacetylation of tubulin is required for fibroblast invasive motility, as inhibition of 
HDAC6 leads to increased in steady state levels of focal adhesion, as well as 
decreased MT dynamics. A decrease in MT dynamics causes an increase focal 
adhesion accumulation and a decreases motility in fibroblast (58). Tubulin 
hyperacetylation is necessary and sufficient to increase cellular adhesion. 
Hyperacetylation of MT due to HDAC6 deficiency results in larger adhesion and 
greater total adhesion area due to affected focal adhesion turnover (58). In 
migratory lymphocytes, however, HDAC6 deacetylase activity is not involved in 
promoting cell migration. It was suggested that HDAC6 may have a scaffolding 
role that are important in lymphocyte migration (59). In terms of trafficking within 
the cells, HDAC6 deacetylation of MT affects endocytosis of EGFR, as well as its 
degradation (46, 60). In cytstic renal epithelial cells, HDAC6 was shown to 
regulate endocytic trafficking of EGFR, as well as its degradation. Inhibition of 
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HDAC6 results in a more stable MT network that allows transport of EGFR 
containing vesicles and further degradation (61).  
 
 Cortactin 
HDAC6’s ability to promote cell motility is facilitated not only through the 
microtubule network but also other factors associated with the actin cytoskeleton. 
Cortactin is a multi-domain protein, that is involved in the regulation of actin 
cytoskeleton and influences cytoskeleton reorganization through extracellular 
and intracellular stimuli (62). Cortactin’s structure is made up of a series of six 
complete and one incomplete repeating sequence arranged in tandem. The 
repeat region of cortactin is involved in its binding activity to F-actin (62). In an 
unstimulated environment, cortactin localizes to the cytoplasm, but upon 
stimulation by growth factors, etc. cortactin relocalizes to the cortical actin 
network. Cortactin is known to be associated with actin-based protusion 
structures, lamellipodia formation, and adhesion (62). The initial step involved in 
cell movement is lamellipodial protrusion. It was shown that lamellipodial 
persistence is enhanced by cortactin through regulation of the Arp 2/3 complex. 
Cells with cortactin knock down expression showed defects in the assembly of 
new adhesions in protrusion, as well as defects in motility and invasion (63). 
Post-translational modification of cortactin is also necessary for its role in cell 
migration and angiogenesis. Indeed, both HDAC6 and another class III HDAC, 
SIRT1, were shown to be involved in one or more of these processes (50, 64, 
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65). Both HDAC6 deacetylase domains are required for the deacetylation of 
cortactin, which alters the binding of cortactin to F-actin (50). Cortactin mutants 
with the ability to neutralize the charged patches, which results in decreased 
binding between cortactin and F-actin, were less motile. This result suggests a 
role for HDAC6 in actin dependent motility through its ability to deacetylate 
cortactin (50). HDAC6 deacetylation of cortactin is also necessary for processes, 
such as angiogenesis, both in vitro and in vivo, as well as migration and 
sprouting in endothelial cells (64). 
 
Heat Shock Protein 90 
The molecular chaperone HSP90, is another acetylated protein that is a 
target of HDAC6 deacetylase activity. Inactivation of HDAC6 leads to 
hyperacetylation of HSP90 causing its disassociation from its cochaperone, p23, 
and hindering its chaperone function (49). In addition, inhibition of HDAC6 results 
in a decreased binding of HSP90 to ATP, and further reduced chaperone 
function of HSP90 with its client protein, Bcr-Abl. This leads to polyubiquitination 
of Bcr-Abl and subsequent depletion of intracellular levels of Bcr-Abl, C-Raf, and 
AKT (11). Cell motility and macropinocytosis are regulated through HDAC6 and 
its substrate, HSP90. HDAC6 and HSP90 association in response to growth 
factors such as platelet-derived growth factor (PDGF), leads to activation of Rac1 
and efficient ruffle formation and cell migration (66).  
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β-Catenin 
β-catenin is another cytoplasmic substrate of HDAC6 that has recently 
emerged (67). β-catenin is a cytoplasmic protein that plays a role in determining 
cell fate through patterns and structure formation (68). β-catenin structurally 
consists of an N terminal, a C terminal, and a middle region domain. The middle 
region domain consists of twelve repeats of forty-two amino acids, that are 
considered to be a single functional unit. Each repeat forms a α-helices and a 
connecting loop (69-71). The sequences of β-catenin repeats vary significantly, 
however, the size and hydrophobic core are highly conserved (69). In addition, 
the repeats serve as the binding site for numerous of β-catenin binding partners 
(70, 71).  
β-catenin is a key effector involved in signal transduction through the 
canonical wnt pathway (72). The wnt pathway is a conserved cascade that is 
involved in the regulation of animal development from Cnidarians to mammals 
(72). Wnt signaling is involved in regulating cell proliferation and differentiation 
and is also involved in gene transcription and cell adhesion (73). Activation of the 
wnt pathway through β-catenin leads to transcriptional activation of wnt-specific 
genes that are important for controlling cell fate in many cells and tissues (72).  
 
Regulation of β-catenin  
Two different pools of β-catenin are usually found in the cell. The first 
being the stable form that is involved in cellular adhesion. It is usually found at 
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the membrane in association with E-cadherin and α-catenin. The second being 
the highly unstable form within the cytoplasm that can be found associated with 
axin and APC and is targeted for proteosomal degradation (68, 74). The stability 
and function of β-catenin is controlled by PTM, such as acetylation and 
phosphorylation. Phosphorylation of β-catenin at sites serine 33, 37, 45 and 
threonine 41 are conserved from drosophila to human (75). Mutations at these 
residues are frequently found in human colon cancer and other malignancies 
(75). It has been determined that β-catenin is phosphorylated from the C-terminal 
to the N terminal starting with serine-45, threonine-41, serine-37 then finally 
serine-33. Knock down of the kinase CK1α diminished β-catenin serine-45 
phosphorylation, as well as the other sites phosphorylation, indicating the 
importance of CK1α in β-catenin control (75). Cytoplasmic β-catenin is regulated 
by the destruction complex consisting of the tumor suppressor proteins axin, and 
adenomatous polyposis coli (APC) and two serine-threonine kinases GSK3 α/β 
and CK1 α (68, 76). In the absence of wnt signaling, β-catenin bound to axin is 
phosphorylated first by CK1 then GSK3 (68). Phosphorylated β-catenin is 
recognized by SCF-βTrCP which is a part of an E3 ligase complex. This leads to 
ubiquitination of β-catenin and ultimately degradation by the proteasome (68). β-
catenin is first phosphorylated by CK1α and this modification is necessary for 
subsequent phosphorylation by GSK-3β, as mutation at serine33 or serine37 
prevents phosphorylation dependent recognition by SCF-βTrCP, but mutation at 
threonine41 or serine45 did not (75). Phosphorylation at these sites therefore 
serves as a SCF-βTrCP recognition motif (74). On the other hand, with activation 
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of the wnt/β-catenin pathway, β-catenin ubiquitination is inhibited, and the 
accumulated β-catenin is translocated to the nucleus and activates its target 
genes (68). 
 Like numerous other non-histone proteins, β-catenin was identified as an 
acetylated protein (67, 77). Acetylation of β-catenin by the HAT, p300/CBP-
associate factor (PCAF), improves β-catenin’s stability through the inhibition of 
ubiquitin-dependent degradation. Acetylation of β-catenin also allows its 
translocation to the nucleus to enhance its transcriptional activity (77). In addition 
to other identified acetylation sites, lysine-49 in its amino (N) terminal region is a 
conserved acetylation site from drosophila to human. It was determined that 
acetylation at lysine-19 and lysine-49 prevents ubiquitation of β-catenin and 
therefore its degradation (77). β-catenin was also shown to be acetylated by 
CREB binding protein (CBP) at lysine-49, a site that is frequently mutated in 
thyroid cancer (78). It was determined that unacetylated lysine-49 is a potent 
activator of the c-Myc genes, and that mutation of β-catenin at lysine-49 does not 
affect β-catenin stability or interaction with the wnt pathway members or β-
catenin nuclear localization (78).  
β-catenin was also shown to be acetylated by p300 at lysine-345 within 
the 6 arm repeat region. Mutation of β-catenin at lysine-49 and lysine-345 
showed a significant reduction in acetylation. Acetylated β-catenin at lysine-345 
by p300 showed increased affinity of β-catenin for TCF4. This interaction 
increases the co-activator function of β-catenin resulting in increased 
transcriptional activity (79). HDAC6 association with β-catenin was shown to be 
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in the presence of epidermal growth factor (EGF). EGF stimulation in cells results 
in translocation of HDAC6 from the cytoplasm to the caveolae membrane, where 
HDAC6 associates with and deacetylates β-catenin on lysine-49. Deacetylation 
of β-catenin by HDAC6, results in β-catenin translocation to the nucleus, where it 
activate target genes, such as c-Myc (67). 
 
Clinical Relevance of HDAC6 
Through deacetylation of its cytoplasmic substrates, HDAC6 was shown to 
promote processes that are involved in oncogenesis, such as cell motility and 
angiogenesis (48, 50, 64). HDAC6 is required for oncogenic transformation 
induced by Ras in primary cell lines. It is also required for the maintenance of 
anchorage independent growth in established cancer cell lines. HDAC6 
deacetylase activity is required for malignant growth in cancer cells in vitro, since 
studies have shown that loss of HDAC6 leads to reduced tumor growth (80). 
HDAC6 protein expression is up-regulated in ovarian cancer cell lines and 
tissues. In addition, HDAC6 was shown to promote ovarian cancer cell motility 
and migration (81). In non-migratory cells, HDAC6 is usually localized to 
punctuate structures around the nuclei, however, in migratory ovarian cancer 
cells, HDAC6 is localized to the leading edge of cells (81). Because of the role 
HDAC6 plays in the cancer disease processes, understanding the mechanism 
through which HDAC6 promotes these processes would be beneficial. 
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An Overview of the Mitogen Activated Protein Kinase Family 
 Protein phosphorylation is a well-known post-translational modification 
that is involved in signal transduction (82). The process of phosphorylation or 
dephosphorylation is a reversible reaction that uses kinases to promote 
phosphorylation and phosphatases in the reverse process (82). 
 The mitogen-activated protein kinase (MAPK) pathway represents an 
evolutionary conserved phospho-relay system that includes the extracellular 
signal regulated kinase (ERK 1/2) family, the p38 kinase family, c-Jun-N terminal 
kinase (JNK) family and ERK5. MAPK can be activated by many cellular signals 
that are then converted into a wide range of cellular responses (82, 83). While 
the ERK-MAPK pathway is activated by growth factor stimulated surface 
receptors, the other MAPKs, namely, p38, JNK and ERK5 are activated by stress 
and growth factors (84). Each of the MAPK signaling axis consists of MAPK 
kinase kinase (MAPKKK) that activates MAPK kinase (MAPKK), which then 
leads to the activation of MAPK through phosphorylation of threonine and 
tyrosine residues within the MAPK activation loop (82). Once the MAPKs are 
phosphorylated, they then phosphorylate serine or threonine residue on their 
downstream target substrates, which are localized to many subcellular locations 
within the cells including the cytoplasm, mitochondria, Golgi, endoplasmic 
reticulum and nucleus (82, 83, 85). The specificity of the MAPK response 
depends on activation of different module and scaffolding protein with respect to 
different stimulus (86). For instance, scaffolding proteins, such as kinase 
suppressor of ras-1 (KSR) and MEK partner 1 (MP1), are found within the ERK-
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MAPK module and mediates ERK pathway activation (87). MAPK regulates 
numerous cellular processes including cell proliferation, cell adhesion, cell cycle 
progression, cell migration, cell survival, differentiation, transcription, metabolism, 
inflammation, stress response, and oncogenesis  (82, 83, 85).  
 
The ERK–MAPK Pathway 
The first elucidated MAPK pathway was that of ERK1/2 MAPK (85). This 
pathway like many other pathways is not a simple linear model, but rather a 
complicated network that can be influenced by other pathways, and scaffolding 
proteins. However, a simplified module of the ERK-MAPK pathway consists of 
sequential phosphorylation and activation of Ras -> Raf -> MEK1/2 -> ERK1/2. 
ERK1 and ERK2 are the last kinases within the pathway, phosphorylating 
approximately two hundred substrates (82, 85).  
Within the ERK-MAPK pathway, growth factors bind to their receptor 
tyrosine kinases, leading to receptor dimerization and auto phosphorylation of the 
receptor tyrosine residue. The phosphorylated tyrosine serves as a docking site 
for adaptor proteins known as growth factor receptor binding protein (Grb2) and 
the exchange factor, son of sevenless (SOS). The assembly of the signaling 
complex leads to Ras activation through which Ras bound guanosine 
diphosphate (GDP) is exchanged for guanosine triphosphate (GTP). This 
exchange causes a conformational change in Ras which allows its binding to Raf 
(88). The Ras family of genes consists of three functional genes, namely H-ras, 
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K-ras and N-ras (89, 90). In quiescent cells, Ras is bound to GDP, however upon 
stimulation by growth factors such as EGF, Ras becomes bound to GTP and is in 
an active form (84). Ras then phosphorylates and recruits Raf kinase to the cell 
membrane, allowing its homo- or hetero- dimerization, leading to its activation. 
On the other hand, Raf activation can be inhibited by phosphatases 2A (PP2A) 
(82, 88). Three Raf genes are found in mammals: A-Raf, B-Raf and C-Raf 
(Raf1), with c-Raf being more ubiquitously expressed (88, 90). Raf consists of an 
N-terminal regulatory domain and a C-terminal kinase domain. Within the N-
terminal regulatory domain are two conserved regions (CR) referred to as CR1 
and CR2. The Ras binding domain and a cysteine rich domain are located in 
CR1. CR2 is a serine/threonine rich domain; and the third conserved domain 
CR3 is located in the kinase domain and is required for Raf activity. Removal of 
the regulator domain leads to an oncogenic kinase referred to as Raf-BxB (88). 
Once Raf is activated, it phosphorylates and activates MEK1 and MEK2 
(MEK1/2) (88, 90). The three different Raf isoforms can all phosphorylate and 
activate MEK1/2 to varying degrees, with B-Raf being the strongest and A-Raf 
the weakest (88). At the amino acid level, MEK1 and MEK2 are 79% identical in 
humans. Once MEK1/2 are activated, they then phosphorylate and activate 
ERK1/2 (90).  
In humans, ERK1 and ERK2 are 84% identical at the amino acid level 
(90). MEK1/2 which can phosphorylate both threonine and tyrosine residues, 
phosphorylates ERK1/2 via a threonine-glutamic acid-tyrosine motif within the 
ERK1/2 activation loop (88). ERK1/2 are predominantly found in the cytosol in 
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quiescent cells. However following serum stimulation, translocation to the 
nucleus increases (91). In vivo experiment showed that while ERK2 absence 
from the cells leads to embryonic lethality (90), ERK1 deficient mice only showed 
minor phenotypic changes. They were viable, fertile and showed normal size. 
However, maturation of the thymocytes was reduced by approximately 50%. In 
addition, there was no difference between MEFs from wild type and ERK1 
deficient mice in terms of growth rate (92). Among many other cellular processes, 
ERK1/2 is important in regulating cell migration shown by several research 
efforts using either dominant-negative ERK or inhibition of the ERK-MAPK 
pathway using siRNA techniques (86, 93, 94). ERK1/2-mediated phosphorylation 
of its substrates, such as myosin light chain kinase (MLCK), caplains and focal 
adhesion kinase (FAK) and the nuclear ETS-domain containing protein, ELK-1, 
were particularly shown to be involved in mediating cell migration (93, 94).  
 
Deregulation within the ERK-MAPK Pathway 
Deregulation of the ERK1/2 pathway is involved in various pathologies 
including neurodegenerative diseases, developmental diseases, diabetes, and 
cancer (85). Over activation of the ERK1/2 pathway can lead to the induction of 
cellular processes seen in the hallmarks of cancer. These processes include 
immortalization, growth factor independent growth, insensitivity to growth 
inhibitory signal, invasion and metastasis, angiogenesis and evading apoptosis 
(88). Deregulation of the ERK-MAPK pathway occurs in approximately 30% of all 
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cancers, including cancer of the pancreas, colon, thyroid, lung and melanoma. 
Mutations occurring in the upstream components of the pathway leads to 
constitutive activation of the phosphorylation cascade (85, 88, 95). Early stages 
that lead to the activation of ERK1/2 are affected in most cancers, e.g tyrosine 
kinase receptor overexpression, mutation in tyrosine kinase receptor that leads to 
its continuous activation, and mutations in Ras or B-Raf (84, 88, 95). The Ras 
genes are frequently found to be mutated in several human tumors. Point 
mutations in the Ras genes result in a protein product with alterations in the 
amino acid at critical positions: 12, 13 or 61 (89). Mutations at these codons lead 
to constitutive Ras activation by preventing efficient GTP hydrolysis (95). 
Mutations upstream of ERK1/2 leads to eventual over activation of the ERK-
MAPK pathway, and further over expression of substrates either in the nucleus or 
the cytoplasm that may promote the processes involved in cancer initiation, 
progression and metastasis. (84) 
The FDA has approved approximately 10 inhibitors of protein kinases, and 
over 100 agents that target kinases which are under clinical investigation (84). 
Numerous research efforts have been focused on inhibitors that target the ERK-
MAPK pathway, since it was shown that ERK-MAPK signaling promotes cell 
proliferation, cell survival and metastasis (84). The MEK inhibitors, such as 
PD98059 and U0126, even though highly specific, lack pharmaceutical 
properties needed for clinical treatment in patients (84). Therefore, there still 
exists a need for research that will help to develop drugs that will target ERK-
MAPK pathway as well as ERK1/2 substrates.  
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Conclusion and Central Hypothesis 
 HDAC6 has been implicated in cell motility through its ability to 
deacetylate its cytoplasmic substrates, thereby affecting the MT and actin 
network. Like other HDACs, HDAC6 can also be regulated by PTM such as 
phosphorylation to either enhance or hinder its deacetylase activity. HDAC6 
expression is up-regulated in many cancer tissues compared to their normal 
tissue counterparts; and animal models have indicated that HDAC6 enhances 
tumor metastasis. Therefore, understanding the mechanisms through which 
HDAC6 promotes cell motility and metastasis would be beneficial to the 
development of pharmacological agents. Based on the published literature and 
our preliminary data, we hypothesized that 1) Phosphorylation of HDAC6 at 
serine1035 promotes cell migration through deacetylation of its substrates and 2) 
HDAC6 promotes cell migration in vivo  
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FIGURE 
 
 
Figure 1.1. A representation of human HDAC6 structure consisting of two 
deacetylase domains (DAC1 and DAC2), the cytoplasmic anchoring motif (SE-
14), and the ubiquitin carboxyl-terminal hydrolase-like zinc finger (ZnF-UBP) 
domain. NES and NLS represent nuclear export signals and a nuclear 
localization signals, respectively. 
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CHAPTER TWO 
HDAC6 SERINE-1035 IS PHOSPHORYLATED BY ERK1 DURING 
ACTIVATION OF THE ERK-MAPK PATHWAY 
 
Abstract 
Histone deacetylase 6 (HDAC6) is a class IIb histone deacetylase family 
member. HDAC6 is mainly localized to the cytoplasm but can also be 
translocated to the nucleus in some instances. Previous studies have reported 
that HDAC6 is a phospho-protein and identified the kinases involved. In this 
study, we used mass spectrometric analysis and identified HDAC6 serine-1035 
as a phosphorylation site located within an extracellular signal regulated kinase 
(ERK1/2) recognition motif. In vitro and in vivo assay further proved that ERK1 
phosphorylates HDAC6 at this site. Using a series of active kinases we show that 
activation of the ERK-MAPK signaling axis promotes phosphorylation of HDAC6 
at this site. On the other hand, use of dominant-negative kinases, HDAC6 
unphosphoryation mimetic HDAC6(S1035A), and MEK inhibitors showed 
diminished phosphorylation of HDAC6, indicating that HDAC6 serine-1035 is a 
major ERK1 phosphorylation site of HDAC6. Since the ERK-MAPK pathway is a 
key target of numerous signaling events, both ERK1/2 and HDAC6 specific 
inhibitors may prove beneficial for future research directions. 
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 Phosphorylation; kinase; deacetylase; acetylation 
 
Abbreviations 
 ATP, adenosine triphosphate; DN, dominant negative; EGFR, epidermal 
growth factor receptor; ERK1/2, Extracellular signal-regulated kinase 1 and 2; 
FBS, fetal bovine serum; GFP, green fluorescent protein; GRK2, G protein-
coupled receptor kinase 2; GSK-3β, Glycogen synthase kinase-3β; HA, 
hemagglutinin; HAT, Histone acetyltransferase; HDAC, histone deacetylase; 
MAPK, mitogen activated protein kinase; MEK, MAP/ERK kinase ;PKCα, protein 
kinase C alpha; sir2, silent information regulator 2; NP-40, nonyl 
phenoxypolyethoxyethanol-40. 
 
Introduction 
Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are 
enzymes involved in modifying core histones through the addition or removal of 
acetyl group from the lysine residue on histone tails (1). Acetylation of core 
histones usually results in transcriptional activation, whereas deacetylation of 
core histones causes transcriptional repression (1). HDACs are grouped into four 
classes based on phylogenetic analysis and sequence homology. They are class 
I (HDACs 1, 2, 3 and 8), class II (HDACs 4, 5, 6, 7, 9, and 10), class IV (only 
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HDAC11) and the silent information regulator 2 (sir2) related family which 
represents the class III HDACs consisting of the sirtuins 1-7 (1-3). Classes I, II 
and IV require Zn2+ as a cofactor to be active, while class III HDACs bearing no 
sequence similarity to class I, II and IV need NAD+ as a cofactor (1). Class I 
HDACs are ubiquitously expressed in many cell types and are found almost 
exclusively in the nucleus. However, the expression pattern of class II HDACs is 
more restricted and they are able to shuttle between the nucleus and the 
cytoplasm in response to cellular signals (4-7). Apart from histones, it is well 
known that HDACs also modify non-histone proteins which in turn regulate the 
functionality of those proteins (8).  
HDAC6 which belongs to the class IIb HDACs is unique among HDACs in 
that it is the only HDAC that contains a complete duplication of the large class I/II 
HDAC homology domain. HDAC6 consists of both a nuclear export signal 
located in the N-terminus and a cytoplasmic anchorage motif known as SE-14 
motif in the C-terminus (9, 10); and a zinc finger motif, which binds to mono- and 
poly-ubiquitin chains (10, 11). HDAC6 is recognized for deacetylating 
cytoplasmic proteins, including α-tubulin (12, 13), cortactin (14), and HSP90 (15). 
HDAC6 associates with microtubules through its HDAC domain and is capable of 
deacetylating α-tubulin at lysine 40 both in vivo and in vitro (13). It is generally 
believed that HDAC6 deacetylation of microtubules and cortactin influences both 
microtubule-dependent and actin-dependent cell motility, respectively (12, 14).  
Recently, phosphorylation sites within HDAC6 as well as the kinases that 
are responsible for phosphorylating these sites have been shown. Glycogen 
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synthase kinase-3β (GSK-3β) is one such kinase. GSK-3β phosphorylates 
HDAC6 at the serine-22 site located in HDAC6’s N-terminus (16). Studies also 
suggest that GSK-3β enhances HDAC6 deacetylase activity towards α-tubulin 
(16). HDAC6 can also be phosphorylated by Aurora A kinase, a centrosomal 
kinase involved in regulating mitotic entry (17). Phosphorylation of HDAC6 by 
Aurora A enhances HDAC6’s ability to deacetylate acetylated α-tubulin to 
promote ciliary disassembly, but the phosphorylation site for this kinase remains 
to be identified (17). Recently, the G protein-coupled receptor kinase 2 (GRK2) 
was shown to phosphorylate HDAC6 and stimulate its α-tubulin deacetylase 
activity (18).  In addition to α-tubulin, phosphorylation of HDAC6 also alters its 
deacetylase activity toward other substrates, such as β-catenin. As reported by 
Zhu et al., protein kinase C alpha (PKCα) enhances HDAC6 deacetylase activity 
towards β-catenin, and further regulates its nuclear translocation and promoter 
binding (19). Besides the serine/threonine kinases, tyrosine kinases such as 
epidermal growth factor receptor (EGFR) kinase also phosphorylates tyrosine 
570 within the HDAC6 C-terminal deacetylase domain, which results in a 
decrease in the deacetylase activity of HDAC6,  an increase in α-tubulin 
acetylation and  altered EGFR trafficking (20). Overall, numerous kinases target 
HDAC6 at different amino acid residues to regulate its activity towards its 
substrate and ultimately influence cell motility and other cellular functions.  
Extracellular signal-regulated kinase 1 and 2 (ERK1/2) are related protein-
serine/threonine kinases from the mitogen activated protein kinase (MAPK) 
family that participate in the EGFR-Ras-Raf-MEK-ERK1/2 signal transduction 
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cascade (21).  ERK1/2 catalyzes the phosphorylation of numerous substrates 
including those of the nucleus, cytoplasm, cytoskeletal proteins and protein of the 
nuclear complex (21).  Downstream targets of ERK1/2 are involved in many 
biological processes including cell adhesion, cell cycle progression, cell survival, 
differentiation, metabolism, proliferation, transcription, and cell migration (21, 22). 
Here, we have identified the cytoplasmic deacetylase HDAC6 as a novel ERK1 
substrate. Our results suggest that HDAC6 associates with ERK1/2 both in the 
nucleus and the cytoplasm, and that activation of the EGFR-Ras-Raf-MEK-
ERK1/2 signaling cascade promote phosphorylation of HDAC6 at serine 1035 
within its C-terminus. 
 
Results 
LC-MS/MS Identifies Threonine-1031 and Serine-1035 of HDAC6 as 
Phosphorylation Sites 
In order to identify novel phosphorylation sites of HDAC6, 293T cells were 
transduced with adenovirus HA-HDAC6-F (14) for 36 hours. The cells were then 
lysed and HDAC6 was immunoprecipitated by anti-Flag antibodies. The 
immunoprecipitates were resolved on SDS-PAGE, then followed by Coomassie 
blue staining. The HDAC6 band was excised and subjected to liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) analyses. As shown in 
Fig. 1A-C, the mass spectrometry analyses identified two novel phosphorylation 
sites located in the C-terminal region of HDAC6, namely threonine-1031 (T1031) 
and serine-1035 (S1035). The extent of HDAC6 phosphorylation on these two 
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sites was also examined by quantitative mass spectrometry. The majority of 
immunoprecipitated wild type HDAC6 was phosphorylated (82.5%) (Fig. 1D), 
suggesting the importance of the T1031 and S1035 sites. Among these two sites, 
S1035 is within the ERK1/2 optimal consensus motif (P-X-S/T-P) (23), whereas 
T1031 is within the ERK1/2 minimal recognition motif (S/T-P) (Fig. 1E). In 
addition, T1031 and S1035 were conserved among rat, mouse, dog and human, 
but not drosophila and fish (Fig. 1E and data not shown). This suggests that 
these sites are conserved in mammals. Although serine-1045(S1045) is also 
located within an ERK1/2 recognition motif, the mass spectrometry analyses did 
not reveal it as a phosphorylation site.  
 
Threonine-1031 and Serine-1035 of HDAC6 are Phosphorylated by 
ERK1 In Vitro 
We next set out to determine whether ERK1/2 is indeed involved in 
phosphorylating these sites. To this end, we used recombinant ERK1 and the C-
terminal fragments of HDAC6 harboring wild type (WT) or mutants, whereby 
Threonine(T) or serine(S) was mutated to alanine(A) (T1031A, S1035A, 
T1031A/S1035A, S1045A) (Fig. 2A) to perform the in vitro kinase assays. Our 
results showed that S1035 was a major phosphorylation site for ERK1 as was 
evidenced by the disappearance of the phosphorylation signal when this site was 
mutated from serine to alanine (Fig. 2B, lane 3). Mutation of the T1031 site to 
alanine, exhibit a moderate decrease in the levels of phosphorylation (Fig. 2B, 
lane 4 vs. lane 2), indicating that the T1031 site is not a major ERK1 
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phosphorylation site. The results also showed that the phosphorylation of T1031 
by ERK1 was dependent on S1035 phosphorylation, because in the double 
mutant, HDAC6(816-1215)T1031A/S1035A, no phosphorylation signal was 
observed (Fig. 2B, lane 5). Moreover, the phosphorylation signal of S1045A was 
comparable to that of the WT (Fig. 2B, lane 6 vs. lane 2), indicating that S1045 
was not phosphorylated by ERK1 in vitro. In addition, we also examined whether 
another MAPK, p38, can phosphorylate the C-terminal region of HDAC6. Our 
analyses indicated that the p38α kinase phosphorylated WT, as well as the 
T1031A, S1035A and S1045A mutants of HDAC6 to similar levels. This suggests 
that T1031, S1035 and S1045 are not p38α phosphorylation sites (data not 
shown). Collectively, the mass spectrometry analyses and the in vitro kinase 
assays have demonstrated that S1035 and T1031 can be phosphorylated by 
ERK1 in vitro, whereas S1045 cannot be phosphorylated.  
 
Serine-1035 of HDAC6 is Phosphorylated Through the EGFR-RAS-
RAF-MEK-ERK Pathway In Vivo 
 After we determined that ERK1 phosphorylated HDAC6 in vitro, we next 
asked whether the phosphorylation by ERK1 also occurred in vivo. Mouse 
embryonic fibroblast (MEFs) were treated with MEK inhibitors, U0126 and 
PD98059. Then immuno-precipitation experiments using phospho-
serine/threonine antibodies were performed to assess the phosphorylation status 
of HDAC6. In comparison to the control, both U0126 (10 µM) and PD98059 (100 
µM) caused a significant decrease in phosphorylation of HDAC6 when ERK1/2 
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was inhibited (Fig. 3A, lane 1 vs. lanes 2 and 3). To validate our results, an active 
form of Ras (RasG12V) was employed to stimulate the Raf-MEK-ERK signaling 
cascade. This allows the examination of whether activation of the ERK-MAPK 
pathway is able to increase HDAC6 phosphorylation. At the same time a 
dominant-negative (DN) form of MEK, MEK(K97A), was transfected into cells to 
block the downstream ERK-MAPK pathway. As shown in Fig. 3B, active Ras 
dramatically increased HDAC6 phosphorylation (lane 3 vs. 2), while DN-MEK 
significantly decreased HDAC6 phosphorylation (lanes 4). Since ERK1/2 is the 
sole substrate of MEK, the above results indicated that ERK1/2 is indeed 
involved in phosphorylating HDAC6 in vivo.  
 We next examined whether HDAC6 phosphorylation is increased by 
upstream kinases of ERK1/2. Since the ERK-MAPK pathway is well established, 
we transfected a constitutively active c-RAF mutant c-RAF-BXB (24, 25) into 
293T cells to activate endogenous ERK1/2. As shown in Fig. 4A, transfected c-
RAF-BXB activated downstream MEK and ERK1/2 kinases (lane 3 vs. lanes 1 
and 2). HDAC6 phosphorylation was significantly increased in c-RAF-BXB 
transfected 293T cells (lane 3 vs. lane 2), showing that HDAC6 was 
phosphorylated in response to the activation of Raf-MEK-ERK pathway. We next 
explored whether the upstream kinase EGFR increases HDAC6 phosphorylation 
as well. As shown in Fig. 4B, active EGFR, EGFR (vIII), was able to elevate 
ERK1/2 activity and modestly increase HDAC6 phosphorylation. Altogether, we 
have shown that EGFR-Ras-Raf-MEK-ERK-MAPK signaling targets HDAC6 in 
vivo. 
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The Serine-1035 Site of HDAC6 is a Major ERK Phosphorylation Site  
Both the mass spectrometry analysis (Fig. 1D) and the in vitro kinase 
assay (Fig. 2) indicated that S1035 of HDAC6 is a predominant phosphorylation 
site. We then examined whether activation of the ERK-MAPK pathway 
phosphorylates HDAC6 at S1035 in vivo. We used HDAC6 WT, as well as 
S1035A mutants of HDAC6 in these studies. As shown in Fig. 4C, active Ras 
(G12V), or active MEK(S218/222D) dramatically increased phosphorylation of 
wild type HDAC6 (lanes 4 and 6 vs. lane 2) but not HDAC6 (S1035A) mutant 
(lanes 5 and 7 vs. lane 2). This result strongly supports that S1035 is a major 
phosphorylation site of HDAC6 targeted by ERK1/2. To further confirm whether 
ERK1/2 phosphorylates HDAC6 at S1035, 293T cells were transiently 
transfected with plasmids for empty vector, HA-HD6-F, HA-HD6(S1035A)-F or 
HA-HD6(S1035D)-F in the absence or presence of c-RAF-BXB. As represented 
by Figure 4D, mutation of HDAC6 at the S1035 site decreased HDAC6 
phosphorylation dramatically. Moreover, since c-RAF-BXB could not increase the 
phosphorylation of HA-HD6(S1035A)-F and HA-HD6(S1035D)-F, this suggests 
that activation of the Raf-MEK-ERK signaling pathway mainly targets the S1035 
site of HDAC6 in vivo.  
We next employed epidermal growth factor (EGF) to activate the ERK-
MAPK pathway and observed HDAC6 phosphorylation. 293T cells were 
transiently transfected with WT HDAC6 or S1035A mutant followed by treatment 
with EGF. As illustrated in Fig. 5, EGF significantly induced phosphorylation of 
WT HDAC6, but not the S1035A mutant, suggesting that EGF-induced HDAC6 
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phosphorylation is via S1035. Together, these data provide compelling evidence 
that HDAC6 C-terminal S1035 is a major phosphorylation site in vivo. 
 
ERK1/2 Associates with HDAC6 both in the Cytoplasm and the 
Nucleus 
Other HDACs including HDAC6 have been shown to interact with kinases 
involved in their phosphorylation (18, 26). Since we determined that HDAC6 can 
be phosphorylated by ERK1, we wonder whether there is a physical interaction 
between ERK1 and HDAC6, and whether HDAC6 is involved in regulating 
phospho ERK1/2 expression. In addition, we observed that MEFs cells 
expressing HDAC6, exhibits reduced phospho kinases compared to their HDAC6 
null counterpart (Fig. 6). To determine whether HDAC6 is associated with 
ERK1/2, bacterial expressed glutathione S-transferase (GST) tagged full length 
or deletions of HDAC6 were used to pull down endogenous ERK1/2 in HeLa S3 
nuclear and cytoplasmic fractions, which were prepared as described in Dignam 
et al. (27). As shown in Fig. 7, HDAC6(1-503) and HDAC6(448-840) shows 
binding in both the nuclear and cytoplasmic fraction. However, reduced 
interaction was observed between ERK1/2 and HDAC6(840-1215), suggesting 
that ERK1/2 effectively binds to HDAC6 N-terminal catalytic domain 1 (DAC1) or 
domain 2 (DAC2), respectively. We further try to determine whether HDAC6 
deacetylase function is involved in the regulation of phospho ERK1/2 protein 
expression. We used transfected 293T cells expressing double mutant of HDAC6 
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catalytic domains, as well as HDACi treatment of normal lung cells, then 
observed protein expression of phospho-ERK1/2 and total-ERK1/2. In both 
instances we did not observe any changes in phospho-ERK1/2 expression (data 
not shown). Further studies are needed to decipher how HDAC6 may regulate 
ERK1/2 phosphorylation.  
 
Discussion 
The HDACs family members are widely regulated by post-translational 
modification such as phosphorylation (28-32). HDAC6 is no exception to 
modification by phosphorylation. Previous studies have shown that HDAC6 can 
be phosphorylated by kinases such as GSK-3β, EGFR kinase, Aurora A and 
GRK2 (16-18, 20). In this study, we have demonstrated that HDAC6 is a novel 
substrate for ERK1. We have also identified S1035 as a major ERK1 
phosphorylation site in HDAC6 C-terminal region. Our results suggest that 
activation of the EGFR-Ras-Raf-MEK-ERK signaling axis induces HDAC6 
phosphorylation at S1035 as depicted by Fig 8. Apart from the S1035 site, we 
have also identified T1031 as a phosphorylation site in HDAC6 (Fig. 1 and 2). As 
shown in Fig.4C, D, and Fig. 5, HDAC6(S1035A) mutant could not efficiently be 
phosphorylated by active Ras, active MEK, active Raf or by the use of EGF. 
These results suggest that the S1035 site is the major site targeted by ERK1. 
Furthermore, the results suggest that the T1031 site may not be important for 
ERK-mediated phosphorylation. Nevertheless, given the proximity of T1031 and 
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S1035, we cannot rule out the possibility that T1031 
phosphorylation/dephosphorylation influences HDAC6 function. Future studies 
employing T1031 phosphorylation or dephosphorylation mimicking single mutant 
(T1031A and T1031D) or T1031 and S1035 double mutants (T1031A/S1035A 
and T1031D/S1035D) are warranted.  
ERK1/2 regulates a wide variety of processes through their actions on 
downstream targets. In the cytoplasm alone over 50 substrates have been 
identified, including cytoskeletal protein regulators and signaling molecules (21). 
In quiescent cells ERK1/2 are found predominantly in the cytosol, but following 
serum stimulation its migration to the nucleus increases (33). Because HDAC6 is 
able to translocate form the cytoplasm to the nucleus (34), and since ERK1/2 
phosphorylate its target both in the cytoplasm and the nucleus (21), it would be 
interesting to determine whether HDAC6 is phosphorylated both in the 
cytoplasm, as well as in the nucleus. We have already shown that ERK1/2 is able 
to bind HDAC6 both in the cytoplasm as well as in the nucleus (Fig. 7). Using 
HDAC6 WT, as well as the S1035 unphosphorylated/phosphorylated mimetics, 
fractionation and immunofluorescence studies were unable to determine any 
differences in HDAC6 protein localization in the cytoplasm or the nucleus (data 
not shown). Since HDAC6 interacts with ERK1/2, it is conceivable to speculate 
that HDAC6 could also regulate ERK1/2. It is possible that HDAC6 modulates 
ERK1/2 acetylation, to affect its phosphorylation and subsequently its enzymatic 
activity.  
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 Location of phosphorylation sites in other class I and II HDACs affects 
their nucleocytoplasmic shuttling, as well as their interactions with other proteins. 
HDAC5 was shown to be phosphorylated by cyclic adenosine monophosphate 
/protein kinase A (cAMP/PKA) which prevents it from leaving the nucleus (35). 
Increased accumulation of HDAC5 in the nucleus enhances association with 
other binding partners such as HDAC3 (36). Previously HDAC4, another class II 
HDAC family member, was reported to be a target of ERK1/2 as well. HDAC4 is 
phosphorylated by ERK1/2 in vitro as well as in cells. In addition, HDAC4 
enhanced localization in the nucleus was associated with higher kinase activity of 
ERK1/2 (26). Recently we were able to generate the anti phospho-serine-1035 
HDAC6 site specific antibody. With further optimization we hope to determine 
subcellular distribution of ERK1/2-mediated phosphorylation of HDAC6. We also 
hope to identify any additional substrates or binding partners of HDAC6 that may 
be involve in cellular processes that are affected by HDAC6.  
The ERK-MAPK pathway is involved in promoting many cellular processes 
involved in the hallmark of cancer such as proliferation, apoptosis, immune 
response, angiogenesis, and metastasis (37). Deregulation of the ERK-MAPK 
pathway therefore contributes to many disease states including cancer (38). The 
ERK-MAPK pathway is of major interest because of the activating mutations 
found upstream particularly at EGFR, Ras and Raf. It is therefore a key target for 
anticancer therapy (38, 39). However, targeting Ras has proven unsuccessful. 
Likewise, Raf and its downstream target also presents with challenges including 
acquired resistance (39). Previously, it was shown that HDAC6 expression is 
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induced upon oncogenic Ras transformation, and that HDAC6 is involved in 
promoting transformation and tumorigenesis (40). This study revealed HDAC6 as 
a novel substrate of ERK1. Since both the ERK pathway and HDAC6 were 
shown to be involved in processes in cancer progression, both ERK1/2 and 
HDAC6 represent effective drug target that can be considered for cancer 
therapy. 
 
Experimental Procedures 
Plasmids, Antibodies, Reagents, and Cell lines 
Double tagged HDAC6 (HA-HDAC6-F) is described in the reference (14). 
The point mutations on this construct were created by QuikChange® XL Site-
Directed Mutagenesis Kit (Stratagene). For HA-HDAC6(S1035A)-F, the primers 
used are : 5’  CCACCAGACCCCCCCAACCGCACCTGTGCAG  3’ and              
5’  CTGCACAGGTGCGGTTGGGGGGGTCTGGTGG 3’. 
For HA-HDAC6(S1035D)-F, the primers used are:  
5’ CCACCAGACCCCCCCAACCGACCCTGTGCAG  3’ and  
5’  CTGCACAGGGTCGGTTGGGGGGGTCTGGTGG  3’.   
GST-HDAC6(816-1215) plasmid was constructed by inserting the PCR-amplified 
HDAC6 sequence derived from HA-HDAC6-F into the SalI/NotI sites of pGEX-
4T1 vector using the following primers: SalI/HDAC6, 
 5’ AGTCGACGGGCCCTGGCCTCAATCACTG  3’ and NotI/HDAC6,  
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5’ AGCGGCCGCTTAGTGTGGGTGGGGCATATCC 3’. Point mutations of 
HDAC6 in this construct were created using the following primers: for  
GST-HDAC6(816-1215) S1045A,   
5' CACCCCAGATAGCTCCCAGTACACTGATTG  3' and  
 5' CAATCAGTGTACTGGGAGCTATCTGGGGTG 3'; for  
GST-HDAC6(816-1215) T1031A/S1035A,  
5’   CCACCAGGCCCCCCCAACCGCACCTGTGCAG  3’ and   
5’   CTGCACAGGTGCGGTTGGGGGGGCCTGGTGG  3’; for  
GST-HDAC6(816-1215)T1031A,   
5’   CCACCAGGCCCCCCCAACCTCACCTGTGCAG  3’ and  
5’  CTGCACAGGTGAGGTTGGGGGGGCCTGGTGG  3’; for  
GST-(816-1215)S1035A,  the primers are the same as used for generation of 
HA-HDAC6(S1035A)-F. The PCR cycle was as follows: 95°C, 1 min; followed by 
95°C, 50 sec; 60°C , 50 sec; 68°C,  20 min for 25 cycles and then 68°C, 30 min.  
GST-HD6, GST-HD6(1-503), GST-HD6(448-840) and GST-HD6(840-1215) 
plasmids were generated by PCR. Detailed information is available upon request.  
C-RAF-BXB was described in (25), HA-Ras(G12V), HA-MEK(K97A) and HA-
MEK(S218/222D) were kind gifts from Dr. Jie Wu. EGFR (vIII) plasmid was 
described by Shen et al. (24).  
Anti-HDAC6 (H300) and anti-EGFR (1005) antibodies were purchased 
from Santa Cruz Biotechnology. Anti-phospho serine/threonine antibody was 
purchased from BD Bioscience. Anti-HA antibody was purchased from Covance. 
Anti-β-tubulin antibody and lipofectamine 2000 reagent were purchased from 
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Invitrogen. Anti-Flag antibody was purchased from Sigma. Anti-ERK1/2 antibody 
(#9102), anti-phospho-ERK1/2 (Thr202/Tyr204) antibody (#9101), anti-c-RAF 
(#9422), anti-phospho-c-RAF antibody (Ser338) (56A6) (#9427), anti-phospho-
MEK1/2 (Ser217/221) antibody (#9121), human EGF, and recombinant Erk1 
kinase (#7416) were purchased from Cell Signaling Inc. U0126 and PD98059 
were purchased from CALBIOCHEM. 
HDAC6 wild type and knockout MEFs, and 293T cells, were cultured in 
DMEM medium with penicillin (100 U/ml), streptomycin (100 mg/ml) and 10% 
fetal bovine serum (FBS) and incubated at 37ºC with 5% CO2. 
 
In Vitro Kinase Assay 
GST fusion proteins containing C-terminus of wild type or mutant of 
HDAC6 as shown in Fig. 2A were incubated with recombinant ERK1 (Cell 
Signaling, Inc.) in the presence of 5 µCi of [γ-32P]ATP, 10 µM ATP and 1X kinase 
buffer (10 mM Tris, pH 7.4, 150 mM NaCl,10 mM MgCl2 ,0.5 mM Dithiothreitol 
(DTT) ) for 30 min at 30 °C. Reactions were terminated by adding SDS loading 
buffer followed by heating at 100 °C for 5 mins. Proteins were separated on 6% 
SDS polyacylamide gel, and phosphorylated proteins were visualized by 
autoradiography.  
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Immunoprecipitation and Immunoblotting 
For immunoprecipitations, cells were lysed in LS buffer (PBS [pH 7.5], 
10% glycerol, 0.1% NP-40, and protease inhibitor cocktail). Lysates were 
incubated with protein A or protein G agarose for 2 hours for pre-clearing prior to 
incubation with the indicated primary antibodies for 12 h at 4°C. Immuno-
complexes were collected, washed four times in lysis buffer, and resolved by 
SDS-PAGE. For immunoblotting, samples were transferred to nitrocellulose 
membranes that were then probed with the indicated antibodies. Bound 
antibodies were detected using a Chemiluminescent Detection Kit (Pierce). 
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Figure.2.1. Threonine-1031 and Serine-1035 are Phosphorylated in HDAC6. 
The peptide was detected at 32.6 minutes in the total ion chromatogram (TIC) 
(A), with mass-to-charge ratio 1068.5189, triply charged, and representing an 
error of 6.8 ppm (B). The tandem mass spectrum matched the following 
sequence, HQTPPTSPVQGTTPQISPSTLIGSLRTLE, indicating that T1031 and 
S1035 (highlighted in red) were phosphorylated; the detection of b
3
, y
22
 and y
23
 is 
consistent with this localization (C). The assignment was made with Mascot with 
a score of 50 and Sequest XCorr 5.62. Analysis showing extracted ion 
chromatograms (EIC) for peptides containing both phosphorylated S1035 and 
unmodified S1035 were extracted using Xcalibur 2.0(Thermo). The peak areas 
under the curves were used to calculate the percentage of phosphorylation (D). 
Upper panel: The consensus ERK1/ERK2 recognition motif. Lower panel: A 
stretch of HDAC6 amino acid sequence showing the conservation of mass 
spectrometry analyses identified two ERK1/ERK2 sites (T1031 and S1035) and a 
putative ERK1/ERK2 site (S1045) among rat, mouse, dog and human (E).  
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Figure.2.2. HDAC6 is Phosphorylated by ERK1 In Vitro at Threonine-1031 
and Serine-1035. (A) The diagram of full length and C-terminus of HDAC6 with 
putative phosphorylation sites. (B) Upper panel: In vitro kinase assays were 
performed with the indicated substrates and recombinant ERK1 as described in 
the Methods section. The reaction mixtures were separated on 6% SDS-PAGE 
and analyzed by autoradiography. The amount and purity of proteins used in the 
kinase assays were shown on a coomassie blue stained gel (lower panel)  
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Figure.2.3. HDAC6 Phosphorylation is Targeted by ERK-MAPK Pathway In 
Vivo. (A) HDAC6 phosphorylation was decreased by MEK inhibitor treatment.  
MEFs were treated with MEK inhibitor U0126 or PD98059 with indicated 
concentration for 1 hr. Endogenous HDAC6 was immunoprecipitated (IP) by anti-
HDAC6 antibodies The phosphorylation status of HDAC6 was measured by 
immunoblotting (IB) using anti-phospho-serine/threonine antibodies. The blot was 
then stripped and reprobed with anti-HDAC6 antibodies. Anti-P-ERK and anti-T-
ERK Western blotting analyses were also performed as indicated. (B) Ras-
induced HDAC6 phosphorylation was attenuated by dominant-negative MEK. 
293T cells were transfected using indicated plasmids. HA and Flag double 
tagged HDAC6 was IP by anti-HA agarose beads. Phosphorylation of HDAC6 
was examined by IB with anti-P-Ser/Thr antibodies. The same membrane was 
then stripped and blotted with anti-HA antibodies to detect the IP efficiency of 
HDAC6, HA-MEK(K97A) and HA-Ras(G12V). Anti-P-ERK, anti-T-ERK and anti-
β-tubulin western blotting was also performed. 
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Figure.2.4. HDAC6 Serine-1035 is a Major Phosphorylation Site Targeted by 
EGFR-RAS-RAF-MEK-ERK Pathway In Vivo. (A) Active c-RAF (c-RAF-BXB) 
increased HDAC6 phosphorylation levels in vivo. 293T cells were transiently 
transfected with empty vector, HA-HD6-F alone or HA-HD6-F with c-RAF-BXB. 
Forty eight hours post transfection, cells were harvested and lysed. 
Phosphorylation of HA-HD6-F was detected by IP Western as indicated. The IP 
efficiency was examined by Western blotting with anti-HA antibody. The activity 
and expression of c-RAF-BXB was examined by Western blotting with anti-P-c-
RAF antibody and anti-T-c-RAF antibody, respectively. The expression and 
activity of MEK and ERK were also examined by the indicated antibodies. Equal 
loading of protein was examined by anti-β-tubulin Western blotting analysis. (B) 
Active EGFR increased HDAC6 phosphorylation levels in vivo. 293T cells were 
transiently transfected with indicated plasmids. Phosphorylation of HA-HD6-F 
was detected by IP Western as indicated. The IP efficiency was examined by IB 
with anti-HA antibodies. The expression and activity of EGFR was examined by 
Western blotting with anti-EGFR and anti-P-ERK antibodies. Anti-T-ERK and 
anti-β-tubulin Western blotting analyses were also carried out. (C) S1035 site is a 
major phosphorylation site of HDAC6. 293T cells were transiently transfected 
with indicated plasmids. Following transfection, cell lysate was immuno-
precipitated using anti-HA beads. Phosphorylation status of HDAC6 (P-HDAC6) 
was determined using anti-phospho-serine/threonine Western blotting analysis. 
The same blot was then stripped and reprobed with anti-HA antibody to examine 
the IP efficiency as well as the levels of HA-MEK(S218/222D) and HA-
Ras(G12V). The anti-P-ERK, anti-T-ERK, and anti-β-tubulin Western blotting 
analyses were also carried out. (D) S1035 site is a major phosphorylation site of 
HDAC6. Upper panel: 293T cells were transiently transfected with indicated 
plasmids. Following transfection cell lysate was immuno-precipitated using anti-
HA beads. Phosphorylation status of HDAC6 (P-HDAC6) was determined with 
anti-phospho-serine/threonine Western blotting analysis. IgG heavy chain (IgG-
H) was also indicated. Lower panel: The same blot was stripped and reprobed 
with anti-HA antibody. 
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Figure.2.5. EGF-Induced Phosphorylation of HDAC6 Wild Type but not 
Unphosphorylation Mimicking Mutant. EGF increased HDAC6 
phosphorylation levels in vivo. 293T cells were transiently transfected with empty 
vector, HA-HD6-F alone or HA-HD6(S1035A)-F. Following 24 hrs post 
transfection, cells were serum starved overnight and treated with 50 ng/ml EGF 
for the indicated times. Phosphorylation of HA-HD6-F or HA-HD6(S1035A)-F was 
detected by IP Western as indicated. The IP efficiency was examined by Western 
blotting using anti-HA antibody. The activity of EGF was examined by Western 
blotting with anti-P-ERK1/2 antibody and anti-T-ERK1/2 antibody. Equal loading 
of protein was confirmed using anti-β-tubulin antibody. 
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Figure.2.6. Phospho-ERK1/2 Protein Expression is Upregulated in HDAC6 
Null MEFs Compared to HDAC6 Wild Type Counterpart. Total protein extracts 
were prepared from HDAC6 wild type and HDAC6 null MEFs. Protein extracts 
were analyzed by western blotting analyses.  
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Figure.2.7. ERK1/2 Interacts with HDAC6. (A) Representative of HDAC6 full-
length and HDAC6 deletion constructs. (B) GST beads or GST beads bound 
proteins generated from each of the constructs were incubated with HeLaS3 
nuclear or cytoplasmic fraction and GST pull-down assays were performed 
followed by anti-ERK1/2 Western blotting analyses. Protein expression was 
shown by coomassie blue staining.  
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Figure.2.8. The working model of HDAC6 phosphorylation following 
activation of ERK-MAPK signaling cascade.  
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CHAPTER THREE 
 
ERK1-MEDIATED PHOSPHORYLATION OF HDAC6 AFFECTS 
DEACETYLATION OF HDAC6’s SUBSTRATES 
 
Abstract 
 The predominantly localized cytoplasmic deacetylase HDAC6 is involved 
in many biological processes within the cell. HDAC6 promotes its function 
primarily through the deacetylation of its non-histone proteins. We used 
phosphorylation and unphosphorylation mimetics of HDAC6 by mutating serine-
1035 to alanine or aspartic acid respectively to determine how HDAC6 
deacetylase function towards its substrate is affected. We showed that 
phosphorylation of HDAC6 at serine-1035 does not affect HDAC6 histone 
deacetylase function or its deacetylase function towards cortactin. However, the 
unphosphorylation mimicking mutant of HDAC6 hinders HDAC6’s ability to 
deacetylate two of its cytoplasmic substrates α-tubulin, and β-catenin. 
Interestingly, we observed that HDAC6 phosphorylation mimicking mutant 
enhances deacetylation of β-catenin similar to that observed in HDAC6 wild type. 
Since the ERK1/2 pathway activation enhances HDAC6 phosphorylation and 
affects HDAC6 function, inhibitors of both ERK1/2 and HDAC6 may prove 
beneficial for future research directions. 
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Abbreviations 
A, alanine; aspartic acid, D; CBP, creb binding protein; CK1, casein kinase 
1; GSK-3β, glycogen synthase kinase 3β; HDAC6, Histone deacetylase 6; HAT, 
histone acetyltranferase; PP2A, protein phosphatase 2A; TDAC, tubulin 
deacetylase; TSA, trichostatin A. 
 
Introduction 
Historically, the HDACs were known for modifying histones with resultant 
transcriptional repression. However, more and more HDACs substrates are 
emerging with involvement in numerous non-histone cellular regulations (1, 2). 
HDAC6 belongs to class IIb classic HDAC family (1). Although HDAC6 is found 
primarily in the cytoplasm, it is also capable of nucleo-cytoplasmic shuttling like 
all the other class II HDAC family members (3). Indeed HDAC6 was observed in 
the nucleus during arrest in cell proliferation (4).  
 Since HDAC6 is predominantly cytoplasmic, it is not surprising that it is 
associated with the microtubule network, which influences cell motility through 
deacetylation of its cytoplasmic substrate α-tubulin (5, 6). HDAC6 also localizes 
to the peri-nuclear and leading edge subcellular region of cells in association with 
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p150glued containing motor complex (5). HDAC6 associates with the C-terminal tail 
of β-tubulin and is recruited to the α/β tubulin dimers or microtubules (6). 
HDAC6’s subcellular localization in close proximity to α-tubulin allows HDAC6 to 
deacetylase α-tubulin on its lysine-40 residue (6).  
The phospho-protein cortactin is a multi-domain protein that binds to the 
actin network through F-actin (7). Cortactin association with the actin network 
has implication in many processes of the cell, including cell migration, invasion, 
neuronal morphogenesis, and tumor cell metastasis (7). Cortactin also promotes 
lamellipodia formation and cell adhesion, which are all processes involved in cell 
movement (7). Cortactin function and interaction with its binding partners can 
also be affected by phosphorylation (7, 8). Phosphorylation of cortactin was 
determined to be important for podosomes and invadopodia formation, which are 
all structures needed for cell invasive potential (7). Cortactin can be deacetylated 
by two different HDAC family members, HDAC6 and SIRT1 (9, 10). In both 
cases, deacetylation of cortactin by either of the two HDACs promoted cell 
migration (9, 10). In addition to cell migration, deacetylation of cortactin by 
HDAC6 is important in regulating angiogenesis both in vitro and in vivo, and 
vessel formation in zebrafish (11).   
β-catenin is another cytoplasmic substrate of HDAC6 (12). β-catenin 
functions as a key effector in the canonical Wnt pathway, which is a conserved 
pathway that participates in regulating animal development from cnidarians to 
mammals (13). β-catenin is also part of the cadherin-based cell-cell connection 
located on the cytoplasmic side of the cell membrane (14). β-catenin binds to the 
83 
 
cytoplasmic domain of type I cadherin and is essential in linking cadherin to the 
actin cytoskeleton through interaction with α-catenin (14). β-catenin-mediated 
activation of the Wnt pathway leads to Wnt specific gene transcriptional 
activation, which regulates cell fate (13). Activation of Wnt pathway signaling 
controls the levels of cytoplasmic free β-catenin, by preventing β-catenin 
degradation by the destruction complex (13). The destruction complex consists of 
scaffold protein axin and APC, glycogen synthase kinase 3β (GSK-3β), casein 
kinase 1(CK1), and protein phosphatase 2A (PP2A) (13). Free β-catenin in the 
cytoplasm is recognized by Axin and APC of the destruction complex. β-catenin 
serine-45 is then phosphorylated by CK1α, priming phosphorylation of additional 
sites such as threonine-41, serine-37 and serine-33 by GSK-3β (15). Once 
phosphorylated, β-catenin associates with the ubiquitin machinery and is 
targeted for degradation (13, 15). Previous studies have also associated HDAC6 
with β-catenin. In the presence of epidermal growth factor (EGF) stimulation, 
HDAC6 translocates from the cytoplasm to the caveolae membrane where it 
associates with and deacetylates β-catenin at lysine-49 residue (12). β-catenin 
deacetylation reduces its phosphorylation on serine-45 and hence its 
degradation, and allows β-catenin nuclear translocation (12).  
In this study we used unphosphorylation and phosphorylation mimetics of 
HDAC6 serine-1035 sites to investigate the functional consequences of 
phosphorylated HDAC6. Our results show that mutation of HDAC6 at the serine-
1035 site differentially affects HDAC6 ability to deacetylate its substrates. 
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Results 
Mutation of HDAC6 at Serine-1035 does not Affect HDAC6 Histone 
Deacetylase Activity 
We previously determined that ERK1 phosphophorylates HDAC6 both in 
vitro and in vivo. Since histones are known nuclear substrates of HDACs (16), we 
set out to determine whether ERK-mediated phosphorylation of HDAC6 at 
serine-1035 is capable of affecting its deacetylase activity towards core histones. 
We used unphosphorylation and phosphorylation mimicking mutants of HDAC6, 
whereby serine-1035 was mutated to alanine (A) or aspartic acid (D) 
respectively. Empty vector, wild type HDAC6, S1035A and S1035D mutants 
were transiently transfected into 293T cells. Wild type and mutant HDAC6 
proteins were immunoprecipitated by anti-Flag M2 agrose beads and subject to 
histone deacetylase (HDAC) assay as described in Experimental Procedures. As 
shown in Fig. 1A, S1035A and S1035D mimicking mutants of HDAC6 did not 
significantly affect HDAC6 enzymatic function towards core histones. 
Additionally, wild type HDAC6, S1035A and S1035D mutants were also purified 
from Sf9 cells and subjected to HDAC assay. As presented in Fig. 1B, S1035A 
and S1035D mimicking mutants did not alter the enzymatic activity towards core 
histone as compared with wild type HDAC6. The expression of wild type and 
mutants of HDAC6 in 293T or Sf9 cells were approximately equal as evidenced 
by Commassie blue staining (Fig. 1). Overall, the above results suggest that 
phosphorylation or dephosphorylation of HDAC6 at S1035 does not influence its 
deacetylase activity using core histone as a substrate.  
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HDAC6 Serine-1035 Mimicking Mutants Display Altered TDAC 
Activity Compared with Wild Type HDAC6 both In Vitro and In Vivo 
α-Tubulin is a well known cytoplasmic substrate of HDAC6 (5, 6). To 
determine whether the phosphorylation status of HDAC6 at its serine-1035 site 
would affect HDAC6 deacetylase activity towards α-tubulin we first preformed in 
vitro assays. First, wild type HDAC6 and its mutants S1035A and S1035D were 
transfected into 293T cells. The proteins were immunoprecipitated by anti-Flag 
M2 agarose beads, and subjected to tubulin deacetylase (TDAC) assays using 
reconstituted microtubules as substrates, described in the Experimental 
Procedures.  As shown in Fig. 2A, S1035A mutant showed stronger TDAC 
activity than wild type HDAC6 and S1035D mutant (lane 3 vs. lanes 2 and 4). 
Trichostatin A (TSA), a pan-HDAC inhibitor, was added to the TDAC reaction to 
serve as a negative control (Fig. 2A, lane 5). Similarly, wild type HDAC6, S1035A 
and S1035D mutant were purified from Sf9 cells and subjected to TDAC assay. 
The Sf9 purified proteins also showed similar results in that the S1035A mutant 
exhibit enhanced activity towards tubulin. In summary, our results indicated that 
HDAC6 S1035 dephosphorylation stimulates HDAC6 TDAC activity in vitro. To 
further examine the impact of S1035A mutant on tubulin deacetylation in vivo, 
HDAC6 wild type or S1035A mutant were transfected into CHO or H1299 cells. 
Whole cell lysates were used to perform immunoblotting analyses. As shown in 
Fig. 2B. S1035A transfected cells possess higher levels of acetylated tubulin, 
suggesting that it harbors lower TDAC activity compared with wild type. 
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Mutation of HDAC6 at Serine-1035 does not Affect HDAC6 
Deacetylase Activity towards Cortactin 
The F-actin binding protein cortactin is one of HDAC6 cytoplamic 
substrate (9). To determine whether HDAC6 and its mutants S1035A and 
S1035D deacetylates cortactin in vivo, we used HDAC6 null mouse embryonic 
fibroblast (MEFs), stably expressing HDAC6 and the mutants to perform western 
blotting analyses. As shown in Fig. 3A, there were no differences between 
HDAC6 and HDAC6 mutants in deacetylating cortactin. To further confirm these 
results, we co-transfected 293T cells with HDAC6 or mutants, HA-cortactin, and 
HA-p300, which is the histone acetyltranferase (HAT) for cortactin. Western 
blotting analyses confirmed that mutation of HDAC6 at S1035 does not affect its 
ability to deacetylate cortactin, because both mutants effectively deacetylated 
cortactin to a similar extent like HDAC6 wild type (Fig. 3B). 
 
HDAC6 Wild Type and S1035D Display Enhanced Deacetylase 
Activity Towards β-Catenin 
β-catenin is a key effector molecule that functions in the canonical wnt 
pathway (13). β-catenin was also determined to be a substrate for HDAC6 (12). 
In addition, EGF stimulation of cells enhances HDAC6 ability to deacetylate β-
catenin (12). Since we determined that EGF stimulates HDAC6 phosphorylation 
through activation of the ERK-MAPK pathway, we wonder whether HDAC6 or its 
S1035 mutants would display deacetylase activity towards β-catenin. Since we 
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were having difficulty observing acetylated levels of β-catenin in 293T cells (Fig. 
4A), we transfected cells with two different HATs of β-catenin, p300 and creb 
binding protein (CBP). Cells transfected with p300 showed both HDAC6 and the 
phosphorylating mimicking mutants S1035D enhances deacetylation of β-
catenin, compared to the S1035A mutants. Interestingly, in the presence of CBP, 
both S1035A and S1035D exhibit diminished deacetylase activity towards β-
catenin compared to HDAC6 wild type (Fig. 4B). To confirm these data we 
performed immunoprecipitation experiments using p300 in both 293T cells and 
H1299 lung cancer cells. As shown in Figure 4C and D, both HDAC6 wild type 
and S1035D mutant enhances deacetylation of β-catenin. 
 
HDAC6 Wild Type and Serine-1035D Mutant Deacetylate β-Catenin in 
the Membrane Compartment  
Previous studies indicated that EGF stimulates HDAC6 localization to the 
cell membrane, where it interacts with and deacetylate β-catenin (12). Therefore, 
we next try to determine whether HDAC6 and the mutants are found at the cell 
membrane to promote deacetylation of β-catenin. We transfected H1299 cells 
with HDAC6 wild type, S1035A or S1035D mutants, then performed fractionation 
studies. As shown in Fig. 5, β-catenin protein is found in both the membrane and 
nuclear factions, but was relatively low in the cytoplasmic fraction. Interestingly, 
HDAC6 and its phosphorylation mimetic S1035D enhances deacetylation of β-
catenin at the membrane compared to the S1035A mutant. However, in the 
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nucleus only HDAC6 wild type enhances deacetylation of β-catenin. As shown by 
the western blotting analyses, HDAC6 and the mutants are expressed to similar 
amounts in each compartment.  
We asked whether binding of HDAC6 or its mutants to β-catenin might 
affect effective deacetylation of this substrate. We used overexpressed β-catenin, 
and HDAC6 wild type or HDAC6 mutants to perform co-immunoprecipitation 
experiment. As shown in Fig. 6A, β-catenin co-precipitated with HDAC6 wild type 
as well as the mutants to similar extent, but not the vector control. This indicated 
that mutation of HDAC6 at the S1035 site does not affect binding of HDAC6 to β-
catenin, but affect effective deacetylation of this substrate.  
We next used EGF to induce HDAC6 phosphorylation then observe 
deacetylation of β-catenin. 293T cells were transfected with HDAC6 wild type or 
S1035A mutant then treated with EGF. HDAC6 and mutant protein were 
immunoprecipitated then immunoblotted with phospho-serine/thereonine 
antibodies to detect phosphorylation of HDAC6. As shown in Fig. 6B (lane 2 vs 4 
and lane 3 vs 5) EGF-induced phosphorylation of HDAC6 but not its S1035A 
mutants. Phospho-ERK1/2 expression indicated up-regulation of the ERK-MAPK 
pathway. Interestingly, HDAC6 in the presence of EGF enhances deacetylation 
of β-catenin (Fig. 6B lane 4 vs 5). Overall these data indicated that 
phosphoryated HDAC6 at S1035 enhances deacetylation of β-catenin.  
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Discussion 
Even though HDAC6 is mainly cytoplasmic, it can shuttle between the 
cytoplasm and the nucleus, based on specific signals (4). In addition a fraction of 
HDAC6 is found in the nucleus during cases of cell cycle arrest (4). Histones 
were the first identified substrates of HDACs (16), and HDAC6 can deacetylate 
histones in vitro (17, 18). In this study we present that ERK-mediated 
phosphorylation of HDAC6 at S1035 within HDAC6 C-terminal affects HDAC6 
deacetylase function. While the use of phosphorylation and unphosphorylation 
mimicking mutants do not affect HDAC6 ability to deacetylation the core 
histones, the cytoplasmic substrates of HDAC6 are differentially deacetylated. 
HDAC6 can be phosphorylated by other kinases including EGFR kinase, 
Aurora A, and GSK-3β (19-21). In all cases, HDAC6’s ability to deacetylase its 
well known cytoplasmic substrate α-tubulin, was affected. For instance, EGFR 
phosphorylates HDAC6 at tyrosine-570 and decreases TDAC activity of HDAC6 
(19). Since we determined that EGFR-Ras-Raf-MEK-ERK signaling activation 
leads to phosphorylation of HDAC6 at a different site, we wonder how this 
modification may affect TDAC activity of HDAC6. In vivo we observed decreased 
TDAC activity by both the S1035A and S1035D mimicking mutants of HDAC6 
(Fig. 2B) and data not shown. It would be interesting to determine how HDAC6 
serine-1035 and tyrosine-570 sites in combination affects α-tubulin acetylation 
and cell migration. It is intriguing that the enzymatic activity of the S1035A mutant 
towards tubulin differs in vitro and in vivo (Fig. 2A and B). One possibility is that 
the cell line used for isolation of HDAC6 complex for in vitro TDAC assay (293T) 
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and the cell lines used for in vivo TDAC assay (CHO and H1299) were different. 
Another possibility is that ERK1/2 was present in the in vivo but not in vitro TDAC 
assays. ERK1/2 is associated with and phosphorylates microtubules (22) which 
may account for the different results of the in vitro and in vivo TDAC assays.   
Cortactin is an F-actin binding protein that plays an essential role in cell 
migration (9-11) and angiogenesis (11). Cortactin is also an HDAC6 substrate 
(9). In our experiments we did not observe any differences in HDAC6 and its 
mutants in the deacetylation of cortactin (Fig. 3). This observation is consistent 
with the fact that ERK1/2 is associated with the microtubules but not with actin or 
intermediate filaments (22).  
 β-catenin is an effector molecule of the canonical Wnt pathway (13). β-
catenin is regulated by phosphorylation, which targets it for degradation by the 
destruction complex (13). β-catenin is also among the emerging list of HDAC6 
substrates (12). It was previous shown that HDAC6 deacetylation of β-catenin at 
lysine-49 is induced by EGF. This stabilizes β-catenin, allowing it to translocate 
to the nucleus where it activates target genes such as c-Myc (12). We used 
S1035A and S1035D mutants of HDAC6 and observed enhanced deacetylation 
of β-catenin in the presence of S1035D mutant, similar to that of HDAC6 wild 
type. We also observed that this deacetylation is enhanced at the cell membrane 
(Fig. 5). This is in agreement with other reports that EGF induces HDAC6 
deacetylation of β-catenin at the cell membrane (12). Mutation in the Wnt/β-
catenin pathway are implicated in several disease process including bone 
disease, and cancer especially in tissues that is dependent on Wnt signaling for 
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renewal or repair (23). β-catenin lysine-49, which is the target of HDAC6 
deacetylase activity, is a conserved site from drosophila to human (24). In 
patients with thyroid carcinomas lysine-49 is mutated to arginine (12). 
Interestingly, the convergences of Wnt-β-catenin with EGFR signaling has been 
observed in many different cancer processes including cancer of the lung, breast 
and colon (25). Our data showed a difference in the HATs, p300 and CBP in 
affecting deacetylation of β-catenin. Both p300 and CBP improves β-catenin 
stability through inhibition of ubiquitin dependent degradation, thus allowing β-
catenin translocation to the nucleus to enhance its transcriptional activity (26). 
The HAT p300, can also acetylate HDAC6 to regulate its TDAC activity and 
nuclear import (27). It is also possible that cross talk between p300 and HDAC6 
enhances HDAC6 activity towards β-catenin as seen in our results.  
It is well documented that HDAC6 supports a role in tumorigenesis (28). In 
addition, HDAC6 deacetylation of its cytoplasmic substrates promotes processes 
involved in promoting cancers, such as cell migration, metastasis and 
angiogenesis. Here we show that ERK-mediated phosphorylation of HDAC6 
affects deacetylation of its substrates that are also involved in these processes. 
β-catenin in particular is a major therapeutic target, because of the role it plays in 
promoting tumorigenesis. Several inhibitors to interrupt various stages of the 
Wnt/β-catenin pathway has remain mainly unsuccessful (23). Because of the 
convergence of ERK-MAPK pathway, HDAC6, and Wnt/β-catenin signaling, it is 
possible that combination inhibitors may be effective in some tumors that are 
promoted by β-catenin up-regulation. 
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Experimental Procedures 
Plasmids, Antibodies, Reagents, and Cell lines 
HA-HD6-F is described in (9). The point mutations on this construct were 
created by QuikChange® XL Site-Directed Mutagenesis Kit (Stratagene). For 
HA-HD6(S1035A)-F, the primers used are : 
5’   CCACCAGACCCCCCCAACCGCACCTGTGCAG  3’ and,  
5’  CTGCACAGGTGCGGTTGGGGGGGTCTGGTGG 3’. 
For HA-HD6(S1035D)-F, the primers used are  
5’ CCACCAGACCCCCCCAACCGACCCTGTGCAG  3’ and  
5’ CTGCACAGGGTCGGTTGGGGGGGTCTGGTGG  3’. The PCR cycle was as 
follows: 95°C, 1 min; followed by 95°C, 50 sec; 60°C , 50 sec; 68°C,  20 min for 
25 cycles and then 68°C, 30 min.  
Anti-HDAC6 (H300) , HSP60, and Total β-catenin antibodies were 
purchased from Santa Cruz Biotechnology. Anti-HA antibody was purchased 
from Covance. Anti-acetylated α-tubulin antibody, anti-β-tubulin antibody and 
lipofectamine 2000 reagent were purchased from Invitrogen. Anti-Flag antibody 
purchased from Sigma. Microtubules (#MT001-A) were purchased from 
Cytoskeleton; Anti-ERK1/2 antibody (#9102), anti-phospho-ERK1/2 
(Thr202/Tyr204) antibody (#9101), Parp, EGF, and acetyl-β-catenin (lys49), were 
purchased from Cell Signaling Inc.  
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CHO, a Chinese hamster ovary cell line, H1299, HDAC6 wild type and 
knockout MEFs, and 293T cells were cultured in DMEM medium with penicillin 
(100 U/ml), streptomycin (100 mg/ml) and 10% fetal bovine serum (FBS) and 
incubated at 37ºC with 5% CO2. 
 
Establishment of Stable Clones 
To generate the rescue clones in HD6 knockout MEFs, empty vector, HA-
HD6-F, HA-HD6(S1035A)-F and HA-HD6(S1035D)-F were transfected into HD6 
knockout MEFs using Lipofectamine Plus reagents. One day after transfection, 
500 µg/ml G418 was added to the medium to select positive cells. Ten days later, 
stable cell lines were subcloned to 60 mm dishes and 300 µg/ml G418 was 
added to maintain the stable clones.  
 
Generation of Baculoviruses 
The baculoviruses expressing HA-HD6-F, HA-HD6(S1035A)-F and HA-
HD6(S1035D)-F were generated from modified pFastBac-HTb donor vector 
(Invitrogen) in which His tag was changed to Flag tag. The bacmids containing 
the above cDNAs were generated by transposition in E.coli cells according to the 
manual of Bac-to-Bac system (Invitrogene). Baculoviruses expressing wild type 
and A or D mutant of HDAC6 proteins were generated by transfection of 
recombinant bacmids into Sf9 cells using CellfectinRII Reagent (Invitrogen).  The 
P2 stocks of baculovirus were used to infect Sf9 cells. The overexpressed HA-
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HD6-F, HA-HD6(S1035A)-F and HA-HD6(S1035D)-F in Sf9 cells were purified 
using anti-Flag M2 agarose (Sigma). 
 
Immunoprecipitation and Immunoblotting 
For immunoprecipitations, cells were lysed in LS buffer (PBS [pH 7.5], 
10% glycerol, 0.1% NP-40, and protease inhibitor cocktail). Lysates were 
incubated with protein A or protein G agarose for 2 hours for pre-clearing prior to 
incubation with the indicated primary antibodies for 12 h at 4°C. 
Immunocomplexes were collected, washed four times in lysis buffer, and 
resolved by SDS-PAGE. For immunoblotting, samples were transferred to 
nitrocellulose membranes that were then probed with the indicated antibodies. 
Bound antibodies were detected using a Chemiluminescent Detection Kit 
(Pierce). 
 
Histone Deacetylase (HDAC) Assay 
 F-vector, HA-HD6-F, HA-HD6(S1035A)-F or HA-HD6(S1035D)-F proteins 
purified from 293T transfected cells lysate were precleared with protein A beads 
and immunoprecipitated with anti- Flag beads before protein deacetylase activity 
was determined. Briefly, [3H]acetate-incorporated histones were isolated from 
butyrate-treated HeLa cells by acid extraction as described in (27). Purified core 
histones (12,000 cpm) were incubated with immunoprecipitates in 150 μl of ice-
cold histone deacetylase buffer (20 mM Tris [pH 8.0], 150 mM NaCl, and 10% 
glycerol) at 37°C for 2 hr. The reaction was terminated by the addition of an 
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equal volume of stop solution (0.16 M acetic acid, 1.0 M HCl) and mixed well by 
vortexing. The released [3H]acetate was extracted with ethyl acetate and 
combined with scintillation mixture for analysis. Additionally, HD6 and its mutants 
(S1035A and S1035D) were also obtained from Sf9 insect cells. The purified 
proteins were used to performed HDAC assay as was done with 293T cells. 
 
Tubulin Deacetylase (TDAC) Assay 
First, 293T cells were transfected with empty vector, HA-HD6-F, HA-
HD6(S1035A)-F or HA-HD6(S1035D)-F plasmid.  After 48 hrs, cells were 
collected and lysed with lysis buffer (PBS [pH 7.5], 10% glycerol, 0.1% NP-40, 
PMSF and protease inhibitor cocktail), pre-cleared with protein A beads then 
immunoprecipitated with anti-Flag beads over night at 4°C. Following incubation, 
beads were washed 3X with lysis buffer containing protease inhibitor. TDAC 
assay was carried out as described (11). Briefly, proteins were eluted with 200 
µg/ml Flag peptide and incubated with 100 µl of 2X TDAC buffer (20 mM Tris-Cl 
pH 8.0, 20 mM NaCl) and 50 µg reconstituted microtubules (Cytoskeleton) in a 
200 µL reaction at 37°C for 2 hrs, then transferred to ice for 15 mins. A fraction of 
the reactions were analyzed by Coomassie blue staining or Western blot analysis 
using anti-α-tubulin and anti-acetylated α-tubulin antibodies. Additionally, wild 
type and mutants of HD6 were also isolated from Sf9 cells and were used to 
perform the TDAC assay. 
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Cell Fractionation 
H1299 cells were transfected with HDAC6 WT or the S1035 mutants. 
Following transfection, cells were collected and cytoplasmic, membrane and 
nuclear fractionation was performed using a fractionation kit purchased from 
Millipore (Cat #2145RF). Collected fraction lysates were then subjected to 
immunoblotting. 
 
Statistics 
Each experiment were performed at least three times. Statistical analysis 
was performed using the student’s t-test. p-value < 0.05 was considered 
significant. 
 
References 
 
1. Yang XJ, Seto E. HATs and HDACs: from structure, function and 
regulation to novel strategies for therapy and prevention. Oncogene. 
2007;26(37):5310-8. Epub 2007/08/19. doi: 10.1038/sj.onc.1210599. PubMed 
PMID: 17694074. 
2. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 
2007;26(37):5420-32. Epub 2007/08/19. doi: 10.1038/sj.onc.1210610. PubMed 
PMID: 17694083. 
97 
 
3. Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile 
regulators. Trends in genetics : TIG. 2003;19(5):286-93. Epub 2003/04/25. doi: 
10.1016/S0168-9525(03)00073-8. PubMed PMID: 12711221. 
4. Verdel A, Curtet S, Brocard MP, Rousseaux S, Lemercier C, Yoshida M, 
et al. Active maintenance of mHDA2/mHDAC6 histone-deacetylase in the 
cytoplasm. Current biology : CB. 2000;10(12):747-9. Epub 2000/06/30. PubMed 
PMID: 10873806. 
5. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, et al. 
HDAC6 is a microtubule-associated deacetylase. Nature. 2002;417(6887):455-8. 
doi: 10.1038/417455a. PubMed PMID: 12024216. 
6. Zhang Y, Li N, Caron C, Matthias G, Hess D, Khochbin S, et al. HDAC-6 
interacts with and deacetylates tubulin and microtubules in vivo. The EMBO 
journal. 2003;22(5):1168-79. Epub 2003/02/28. doi: 10.1093/emboj/cdg115. 
PubMed PMID: 12606581; PubMed Central PMCID: PMC150348. 
7. Ammer AG, Weed SA. Cortactin branches out: roles in regulating 
protrusive actin dynamics. Cell motility and the cytoskeleton. 2008;65(9):687-
707. Epub 2008/07/11. doi: 10.1002/cm.20296. PubMed PMID: 18615630; 
PubMed Central PMCID: PMC2561250. 
8. Kelley LC, Hayes KE, Ammer AG, Martin KH, Weed SA. Cortactin 
phosphorylated by ERK1/2 localizes to sites of dynamic actin regulation and is 
required for carcinoma lamellipodia persistence. PloS one. 2010;5(11):e13847. 
doi: 10.1371/journal.pone.0013847. PubMed PMID: 21079800; PubMed Central 
PMCID: PMC2973953. 
98 
 
9. Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, Koomen J, et al. 
HDAC6 modulates cell motility by altering the acetylation level of cortactin. 
Molecular cell. 2007;27(2):197-213. Epub 2007/07/24. doi: 
10.1016/j.molcel.2007.05.033. PubMed PMID: 17643370; PubMed Central 
PMCID: PMC2684874. 
10. Zhang Y, Zhang M, Dong H, Yong S, Li X, Olashaw N, et al. Deacetylation 
of cortactin by SIRT1 promotes cell migration. Oncogene. 2009;28(3):445-60. 
Epub 2008/10/14. doi: 10.1038/onc.2008.388. PubMed PMID: 18850005. 
11. Kaluza D, Kroll J, Gesierich S, Yao TP, Boon RA, Hergenreider E, et al. 
Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by 
deacetylation of cortactin. The EMBO journal. 2011;30(20):4142-56. doi: 
10.1038/emboj.2011.298. PubMed PMID: 21847094; PubMed Central PMCID: 
PMC3199386. 
12. Li Y, Zhang X, Polakiewicz RD, Yao TP, Comb MJ. HDAC6 is required for 
epidermal growth factor-induced beta-catenin nuclear localization. The Journal of 
biological chemistry. 2008;283(19):12686-90. Epub 2008/03/22. doi: 
10.1074/jbc.C700185200. PubMed PMID: 18356165. 
13. Valenta T, Hausmann G, Basler K. The many faces and functions of beta-
catenin. The EMBO journal. 2012;31(12):2714-36. Epub 2012/05/24. doi: 
10.1038/emboj.2012.150. PubMed PMID: 22617422; PubMed Central PMCID: 
PMC3380220. 
 
99 
 
14. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin 
pathways. Science. 2004;303(5663):1483-7. Epub 2004/03/06. doi: 
10.1126/science.1094291. PubMed PMID: 15001769; PubMed Central PMCID: 
PMC3372896. 
15. Amit S, Hatzubai A, Birman Y, Andersen JS, Ben-Shushan E, Mann M, et 
al. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular 
switch for the Wnt pathway. Genes & development. 2002;16(9):1066-76. Epub 
2002/05/10. doi: 10.1101/gad.230302. PubMed PMID: 12000790; PubMed 
Central PMCID: PMC186245. 
16. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from 
bacteria and yeast to mice and men. Nature reviews Molecular cell biology. 
2008;9(3):206-18. doi: 10.1038/nrm2346. PubMed PMID: 18292778; PubMed 
Central PMCID: PMC2667380. 
17. Zhang Y, Gilquin B, Khochbin S, Matthias P. Two catalytic domains are 
required for protein deacetylation. The Journal of biological chemistry. 
2006;281(5):2401-4. doi: 10.1074/jbc.C500241200. PubMed PMID: 16272578. 
18. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. 
Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-
mediated tubulin deacetylation. Proceedings of the National Academy of 
Sciences of the United States of America. 2003;100(8):4389-94. doi: 
10.1073/pnas.0430973100. PubMed PMID: 12677000; PubMed Central PMCID: 
PMC153564. 
 
100 
 
19. Deribe YL, Wild P, Chandrashaker A, Curak J, Schmidt MH, Kalaidzidis Y, 
et al. Regulation of epidermal growth factor receptor trafficking by lysine 
deacetylase HDAC6. Science signaling. 2009;2(102):ra84. doi: 
10.1126/scisignal.2000576. PubMed PMID: 20029029. 
20. Pugacheva EN, Jablonski SA, Hartman TR, Henske EP, Golemis EA. 
HEF1-dependent Aurora A activation induces disassembly of the primary cilium. 
Cell. 2007;129(7):1351-63. Epub 2007/07/03. doi: 10.1016/j.cell.2007.04.035. 
PubMed PMID: 17604723; PubMed Central PMCID: PMC2504417. 
21. Chen S, Owens GC, Makarenkova H, Edelman DB. HDAC6 regulates 
mitochondrial transport in hippocampal neurons. PloS one. 2010;5(5):e10848. 
doi: 10.1371/journal.pone.0010848. PubMed PMID: 20520769; PubMed Central 
PMCID: PMC2877100. 
22. Reszka AA, Seger R, Diltz CD, Krebs EG, Fischer EH. Association of 
mitogen-activated protein kinase with the microtubule cytoskeleton. Proceedings 
of the National Academy of Sciences of the United States of America. 
1995;92(19):8881-5. PubMed PMID: 7568036; PubMed Central PMCID: 
PMC41071. 
23. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell. 
2012;149(6):1192-205. Epub 2012/06/12. doi: 10.1016/j.cell.2012.05.012. 
PubMed PMID: 22682243. 
 
 
101 
 
24. Winer IS, Bommer GT, Gonik N, Fearon ER. Lysine residues Lys-19 and 
Lys-49 of beta-catenin regulate its levels and function in T cell factor 
transcriptional activation and neoplastic transformation. The Journal of biological 
chemistry. 2006;281(36):26181-7. Epub 2006/07/20. doi: 
10.1074/jbc.M604217200. PubMed PMID: 16849322. 
25. Hu T, Li C. Convergence between Wnt-beta-catenin and EGFR signaling 
in cancer. Molecular cancer. 2010;9:236. doi: 10.1186/1476-4598-9-236. 
PubMed PMID: 20828404; PubMed Central PMCID: PMC2944186. 
26. Ge X, Jin Q, Zhang F, Yan T, Zhai Q. PCAF acetylates {beta}-catenin and 
improves its stability. Molecular biology of the cell. 2009;20(1):419-27. Epub 
2008/11/07. doi: 10.1091/mbc.E08-08-0792. PubMed PMID: 18987336; PubMed 
Central PMCID: PMC2613091. 
27. Liu Y, Peng L, Seto E, Huang S, Qiu Y. Modulation of histone deacetylase 
6 (HDAC6) nuclear import and tubulin deacetylase activity through acetylation. 
The Journal of biological chemistry. 2012;287(34):29168-74. doi: 
10.1074/jbc.M112.371120. PubMed PMID: 22778253; PubMed Central PMCID: 
PMC3436516. 
28. Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T, et al. The 
cytoplasmic deacetylase HDAC6 is required for efficient oncogenic 
tumorigenesis. Cancer research. 2008;68(18):7561-9. doi: 10.1158/0008-
5472.CAN-08-0188. PubMed PMID: 18794144; PubMed Central PMCID: 
PMC2978070. 
 
102 
 
FIGURES 
 
 
 
Figure.3.1. Substitution of Serine-1035 to A or D does not affect HDAC6 
Enzymatic Activity Towards Core Histones. (A) 293T cells were transiently 
transfected with the indicated plasmids as indicated. HDAC6 wild type or mutant 
complexes were immunoprecipitated by anti-Flag M2 agarose beads, then 
subjected to the HDAC assay as described in the Experimental Procedures. The 
purified HDAC6 wild type or mutant complexes used in the HDAC assays were 
also shown by Coomassie blue staining. (B) Sf9 cells were transduced by the 
indicated viruses. HDAC6 wild type or mutant proteins were purified by anti-Flag 
M2 agarose and then subjected to the HDAC assays as (A). The purified HDAC6 
wild type or mutant proteins used in the HDAC assays were also shown by 
Coomassie blue staining. Data shown are representative of at least three 
repeated experiments. NS stands for not significant.  
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Figure.3.2. Serine-1035 HDAC6 Mutants Display Altered TDAC Activity 
Compared with the wild Type In Vitro and In Vivo (A)293T cells were 
transiently transfected with the indicated plasmids as indicated. HDAC6 wild type 
or mutant complexes were immunoprecipitated by anti-Flag M2 agarose beads, 
then subjected to the TDAC assay as described in the Experimental section. The 
purified HDAC6 wild type or mutant complexes used in the TDAC assays were 
also shown by Coomassie blue staining.  Sf9 cells were transduced by the 
indicated viruses. HDAC6 wild type or mutant proteins were purified by anti-Flag 
M2 agarose and then subjected to TDAC assays as before. The purified HDAC6 
wild type or mutant proteins used in the TDAC assays were also shown by 
Coomassie blue staining. (B) CHO and H1299 cells were transfected with the 
indicated plasmids. After thirty six hours, cells were harvested and lysed. Anti-Ac-
tubulin and anti-HA Western blotting analyses were performed. 
 
A 
B 
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Figure.3.3. HDAC6 Wild Type, HDAC6(S1035A), and HDAC6(S1035D) Exhibit 
Similar Ability to Deacetylate Cortactin in MEFs or 293T Cells. (A) Western 
blotting analyses were performed using HDAC6KO MEFs stably expressing 
empty vector, HA-HD6-F, HA-HD6(S1035A)-F or HA-HD6(S1035D)-F with 
indicated antibodies. (B) 293T cells were transfected with indicated plasmids. 
The Western blotting analyses were carried out with indicated antibodies.  
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Figure.3.4. HDAC6 Wild Type and HDAC6(S1035D) Phosphorylation 
Mimicking Mutants Enhances Deacetylation of β-Catenin. (A, B) 293T cells 
were transfected with indicated plasmids. The Western blotting analyses were 
carried out using indicated antibodies. (C) H1299 cells (D) 293T cells were 
transiently transfected with the plasmids as indicated. HDAC6 wild type or mutant 
complexes were immunoprecipitated by anti-HA beads, followed by western 
blotting analysis using the ac-β-catenin(lys49) antibodies. The same blots were 
then stripped and reprobed with anti-HA antibodies. 
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Figure.3.5. HDAC6 Wild Type and HDAC6(S1035D) Phosphorylation 
Mimicking Mutants Enhances Deacetylation of β-Catenin at the Cell 
Membrane. H1299 cells were transiently transfected with the plasmids as 
indicated. 36 hrs following transfection, cells were collected and subjected to 
fractionation using a fractionation kit (Millipore) following the manufacture’s 
protocol. A direct western blot analysis was performed using the indicated 
antibodies. EGFR, HSP60 and PARP antibodies were used as membrane, 
cytoplasmic and nuclear fractions markers respectively.  
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Figure.3.6. HDAC6 Binds to β-Catenin and Enhances its Deacetylation 
during EGF Stimulation. (A) 293T cells were transfected with indicated 
plasmids. HDAC6 wild type or mutant complexes were immunoprecipitated by 
anti-Flag beads, followed by western blotting analysis with the indicated 
antibodies. The same blots were then stripped and reprobed with anti-HA 
antibodies. (B) 293 T cells were transfected with the indicated plasmids. 36 hrs 
following transfection, cells were stimulated with 50 ng/mL EGF for 2 mins.  
HDAC6 wild type or mutant complexes were immunoprecipitated by anti-HA 
beads, followed by western blotting analysis using the indicated antibodies. A 
direct western blotting analysis were carried out to determine the expression of 
ac-β-catenin(lys49), total β-catenin, p-ERK1/2, T-ERK1/2, and β-tubulin. 
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CHAPTER FOUR 
 
HDAC6 REGULATES CELL MIGRATION 
BOTH IN VITRO AND IN VIVO 
 
Abstract 
The predominantly cytoplasmic histone deacetylase 6 (HDAC6) is 
involved in promoting cell proliferation, cell migration, metastasis and 
angiogenesis, which are all hallmarks of cancer. HDAC6 is overexpressed in 
several cancer models and is required for efficient oncogenic transformation and 
tumor formation. In this study we report that activation of the ERK-MAPK 
pathway promotes cell migration in mouse embryonic fibroblasts (MEFs) cells in 
an HDAC6-dependent manner. An unphosphorylation mimicking mutant of 
HDAC6’s serine-1035 site significantly reduced the migration potential of MEFs 
compared with HDAC6 wild type or the phosphorylation mimicking mutant. Our 
data suggest that HDAC6 promotes cell migration through two of its cytoplasmic 
substrates, α-tubulin and β-catenin. In addition, for the first time we reported 
evidence to support the hypothesis that HDAC6 promotes in vivo cell migration in 
a mouse model. Given that both HDAC6 and the ERK-MAPK pathway are of 
interest in drug inhibitors studies, targeting both maybe beneficial for future 
studies. 
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Abbreviations 
ERK, extracellular signal regulated kinase; EMT, epithelial mesenchymal 
transition; HAT, histone acetyltransferase; HDAC, histone deacetylase; HDAC6, 
histone deacetylase 6; HDACi, histone deacetylase inhibitors; HGF, hepatocyte 
growth factor; HSP90, heat shock protein 90;  MAPK, mitogen activated protein 
kinase; MEF, mouse embryonic fibroblasts; MEK, MAPK ERK kinase;  MLC, 
myosin light chain; MLCK, myosin light chain kinase; TGF-β, transforming growth 
factor beta.  
 
Introduction 
Acetylation and deacetylation are reversible processes that are catalyzed 
by histone acetyltransferase (HATs) and histone deacetylases (HDACs), 
respectively (1). In addition to modifying histones, HATs and HDACs are involved 
in modifying numerous non-histone proteins that are important in regulating 
cellular processes in both eukaryotic and prokaryotic systems (1-3). These non-
histone proteins function in DNA repair, transcription, replication, apoptosis, and 
signaling (4). In addition, many of these proteins are chaperones, metabolic 
enzymes, cytoskeletal proteins or viral proteins (4). In particular, HDACs are 
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involved in regulating the hallmarks of cancer, which includes, apoptosis, 
angiogenesis, proliferation, cell cycle progression, migration, metastasis, and cell 
differentiation (5). As a result, numerous research efforts are aimed at using 
histone deacetylase inhibitors (HDACi) alone, or in combination with other drugs 
for treatment of various cancers as well as neurodegenerative disorders (6, 7). 
However, because HDACs regulate diverse cellular functions, additional 
research is needed to identify how specific HDACs promote their functions, as 
well as better understand how HDACi achieve their anti-tumor effect.  
The predominantly localized cytoplasmic deacetylase, HDAC6, is one of 
the HDACs that are known to regulate some of the hallmarks of cancer (8-11). 
HDAC6 regulates multiple cytoplasmic processes through the deacetylation of its 
cytoplasmic substrates α-tubulin, cortactin, heat shock protein 90 (HSP90) and β-
catenin (9, 10, 12, 13). The first cytoplasmic substrate of HDAC6 shown to 
regulate cell migration was α-tubulin (9). It was shown that overexpression of 
HDAC6 promotes chemotactic cell movement and that HDAC6-mediated 
deacetylation of microtubules promotes cell motility (9). HDAC6 deacetylation of 
α-tubulin is also required to promote invasive cell motility, and increase total focal 
adhesion area (14). Acetylation and deacetylation of tubulin affects microtubules 
dynamic (15). Additionally, HDAC6 deacetylates α-tubulin and promotes 
microtubule disassembly (15). Tran et al., showed that inhibition of HDAC6 in 
cells, results in decreased microtubule dynamic leading to increased focal 
adhesion accumulation and decreased in fibroblast motility (14). HDAC6 is also 
required for invadopodia formation and function through possible deacetylation of 
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its cytoplasmic substrates α-tubulin and cortactin, and is required for breast 
cancer cell invasion (16).  
 β-catenin, another cytoplasmic substrate of HDAC6, is the central 
molecule of the canonical Wnt pathway (13). β-catenin is usually found at the cell 
membrane tethered to E-caderin. This β-catenin and E-cadherin interaction is 
regulated by phosphorylation (17). β-catenin promotes epithelial cell migration, 
and its stabilized form supports tumor formation in the mouse xenograft model 
(18). In addition, c-Myc, a nuclear target of β-catenin, plays a significant role in 
various disease states including cancer (19, 20). Inhibiting HDAC6 deacetylation 
of β-catenin, prevents β-catenin nuclear localization and consequently decreases 
activation of c-Myc expression (13). HDAC6 was shown to associate with β-
catenin through a complex with glycoprotein CD133 (21). Down-regulation of 
HDAC6, as well as CD133 leads to increased acetylation of β-catenin and its 
degradation, which correlates with decreased in vitro proliferation, colony 
formation, invasion, and decrease in tumor xenograft growth in vivo (21).  
HDAC6 also plays a role in tumorigenesis (22). HDAC6 expression is 
induced upon oncogenic Ras, and HDAC6 is required for efficient oncogenic 
transformation and tumor formation (22). Inactivating HDAC6 decreases 
anchorage independent growth in several cell lines and also reduces tumor 
formation in mice (22). HDAC6 decreases ciliary expression, and targeting 
HDAC6 in cholangiocarcinoma cell line model decreases the tumorigenic 
phenotype of cell in vitro and in an animal model (23). Epithelial mesenchymal 
transition (EMT) is a key event involved in tumor progression (24). HDAC6 
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modulates transforming growth factor beta (TGF-β)-induced EMT by 
deacetylating α-tubulin in human lung epithelial cells (25). In addition, HDAC6 is 
required for growth factor-induced activation of other pathways including the 
extracellular signal regulated kinase (ERK) mitogen activated protein kinase 
(MAPK) signaling pathway (22).  The ERK-MAPK signaling pathway has a pivotal 
role in tumor promotion because of the activating mutations found upstream in 
the pathway (26). The downstream kinases ERK1 and ERK2 phosphorylate 
countless substrates both in the cytoplasm and the nucleus (27). In fact, 
downstream substrates of ERK1/2 found both in the cytoplasm and nucleus were 
shown to promote cell migration (28-30).  
In this study, we showed that ERK-mediated phosphorylation of HDAC6, a 
novel substrate of ERK1, promotes cell migration in mouse embryonic fibroblasts 
cells through deacetylation of its cytoplasmic substrates α-tubulin and β-catenin. 
In addition, HDAC6 also promotes cell migration in vitro in a lung cancer cell line 
model and in vivo using tail vein migration model.   
 
Results 
Active C-Raf-Mediated Cell Migration is via HDAC6 
Cell migration in fibroblast cells lines such as NIH 3T3 cells have 
previously been used to study 2D model cell migration, and results have 
indicated that HDAC6 promotes chemotactic cell movement (9). After we 
identified HDAC6 as a novel substrate of ERK1, we wonder whether the ERK-
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MAPK signaling cascade influenced cell migration via HDAC6. ERK1/2 was 
previously shown to promote cell migration by phosphorylating one of its 
cytoplasmic substrates myosin light chain kinase (MLCK) to promote cell 
migration (31).  We therefore overexpressed active cRaf (cRaf-BxB) in wild type 
or HDAC6 null MEFs and performed migration studies. We employed a transwell 
migration filter whereby serum starved cells were seeded on the top of a 
membrane coated with collagen and allowed to migrate to a lower compartment 
attracted by serum.  As shown in Fig.1A, active cRaf significantly increased cell 
migration in wild type MEFs compared with HDAC6 null MEFs in the migration 
assay. Indeed, active cRaf leads to elevated phospho-ERK1/2 levels in both wild 
type and HDAC6 null MEFs Fig. 1C. (lanes 3 and 4), indicating activation of the 
ERK-MAPK pathway. Interestingly, HDAC6 null MEFs possessed higher 
phospho-ERK1/2 levels compared with wild type (lane 2 vs. lane1). This 
observation raised the possibility that HDAC6 plays a role in suppressing ERK1/2 
activity. Further examination will be warranted.  
 
Unphosphorylation of HDAC6 at Serine-1035 Exerts Lower Migration 
Potential Compared with Wild Type HDAC6 
Since we observed a difference in migration potential in HDAC6 wild type 
cells due to activation of the ERK-MAPK pathway (Fig.1), we next used HDAC6 
null MEFs stably expressing an unphosphorylation or phosphorylation S1035 
mimicking mutant of HDAC6 and performed migration studies.  As shown in Fig. 
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2A and B, S1035A-rescued clone in HDAC6 null MEFs displayed lower migration 
potential compared with HDAC6 wild type and S1035D mutant. Protein 
expression in those rescued clones was approximately equal (Fig.6C). 
Interestingly, we observed that the unphosphorylated form of HDAC6 also 
inhibits deacetylaion of α-tubulin in vivo. Others have shown that use of an 
HDAC6 specific inhibitor as well as, a catalytically inactive HDAC6 mutant 
showed that inhibiting deacetylation of α-tubulin results in retarded cell motility (9, 
32). Our results indicate that dephosphorylation of HDAC6 decreased its ability to 
induce cell migration, and agreed with others that deacetylaion of α-tubulin plays 
a role in promoting cell migration. 
 
β-Catenin is Involved in HDAC6-Mediated Cell Migration 
Since the phosphorylation mimicking mutant of HDAC6 showed enhanced 
cell migration compared to the unphosphorylation mutant, we wonder whether 
ERK1-mediated phosphorylation of HDAC6 could promote cell migration via 
another one of HDAC6 cytoplasmic substrate. β-catenin was previously shown to 
promote cell migration (18). Interestingly, epidermal growth factor (EGF) 
treatment enhances HDAC6 ability to deacetylate β-catenin (13). And in a 
separate study, EGF treatment enhanced cell migration in a β-catenin dependent 
manner (18). As such, we hypothesized that β-catenin is a possible target of 
phosphorylated HDAC6 and can promote cell migration via the EGF-activated 
ERK-MAPK pathway. We therefore used HDAC6 wild type MEFs cells to 
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transiently knock down β-catenin protein using siRNA technique, then performed 
migration studies. Our data illustrated that β-catenin knock down significantly 
decreases cell migration in comparison to the control siRNA group (Fig. 3A and 
B).suggesting that β-catenin is indeed involved in cell migration. 
 
 HDAC6 Promotes Human Lung Cancer Cell Migration In Vitro and In 
Vivo  
Previous studies indicated that HDAC6 promotes tumorigenesis (21, 22, 
33). Several studies have also indicated HDAC6’s role in promoting cell migration 
using different cell line models (9, 10, 32). However, in vivo migration models 
have not been shown. We wondered whether HDAC6 would promote cell 
migration in a mouse model. We used two different human lung cancer cell lines 
for this study. First, H292, a pulmonary carcinoma cell line derived from lymph 
node metastasis; and A549, an epithelial lung carcinoma cell line. In addition, the 
A549 cells expressed the luciferase genes. Both cell lines were stably depleted 
of HDAC6. Western blotting analyses indicated down regulation of HDAC6 
compared to the control group, (Fig. 4A and 5A). We then performed migration 
and invasion studies using the transwell migration technique. For migration 
studies, collagen I was used to coat the transwell chambers, while matrigel was 
used to coat the transwell chambers for invasion studies. We observed that in 
H292 cells, there was a significant difference in HDAC6 ability to promote both 
cell migration and invasion compared to the HDAC6 knock down cells (Fig. 4B, 
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C). Similar data was also observed in a wound healing assay for cell migration 
(data not shown). Interestingly, in the A549 cells, we did not observe a significant 
difference in HDAC6’s ability to promote cell migration and invasion using a 
transwell migration model or wound healing migration model (data not shown). 
We next wanted to determine whether HDAC6 would promote cell 
migration and metastasis in vivo, therefore, we used athymic nude mice to 
perform tail vein injections and allowed cells to migrate for a six week period. 
Because H292 cells were not luciferase tagged, we weighed the mice weekly to 
observe any differences in weight between the HDAC6 wild type and HDAC6 
knock down groups. At the end of the six weeks period we removed the lungs 
and performed a macroscopic analysis of the lungs and surrounding organs for 
the presence of nodules. We did not observe any significant difference in weight 
between the HDAC6 wild type and knock down groups (Fig. 4D). But we 
observed in the HDAC6 wild type group the presence of numerous nodules on 
the surface of the lungs, as compared to the HDAC6 knock down group (Fig. 4E 
and F). However, the difference was not significant owing to the smaller sample 
size.  
Because the A549 cells were luciferase tagged we injected the mice 
weekly with the luciferase substrate luciferin, and observed growth of the cells 
using ex vivo imaging. As illustrated in Fig. 5B, cells were present in the lungs of 
the mice on the day of cell injection via the tail vein (Day 0), indicating a 
successful injection. At the end of the six weeks period we also performed a 
macroscopic analysis of the lungs and surrounding organs for the presence of 
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nodules. Similar to the H292 group, we did not observed any differences in the 
HDAC6 wild type and knock down groups in terms of mice weight (Fig. 5C). 
However, we observed a significant difference in the number of nodule present 
on the surface of the lungs in the HDAC6 wild type group compared to HDAC6 
knock down group (Fig. 5D and E).  
For both the H292 and A549 groups we did not observe any nodules on 
other surrounding organs or tissues other than the lungs. Overall, our results 
supports that HDAC6 can also promote cell migration of human cancer cell lines 
in vitro and in vivo using a mouse model. 
 
HDAC6 Protein Expression is Up-Regulated in a Panel of Lung 
Cancer Cell Lines Compared to Normal Lung Cells 
Others reported that HDAC6 mRNA and protein levels are up-regulated in 
cancer cells and tissues compared to the normal (34-36), as such, we performed 
western blotting analyses on a panel of normal lung and lung cancer  cell lines. 
LL24 and HBE4 are from normal fibroblasts and epithelial cells, respectively. As 
presented in Fig. 6, we observed that HDAC6 protein is mainly up-regulated in 
the other cell lines compared to LL24 and HBE4. Interestingly, cell lines from 
H2122 to H292 were derived from a metastatic site, and we observed that 
HDAC6 expression was much lower in these cell lines. Further studies are 
needed to determine whether this trend have any significance. In addition, 
acetylated β-catenin levels are decreased in the cell lines derived from metastatic 
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sites. This may be a reflection of β-catenin involvement in promoting cell 
migration and tumor formation (18, 37). EGFR and phospho-ERK1/2 protein 
expression is also up-regulated in the majority of these cells lines. This is not 
surprising because numerous studies have implicated that both EGFR and 
ERK1/2 as major players in tumorigenesis (26). 
 
Discussion 
In this study we presented evidence to support the hypothesis that 
phosphorylation of HDAC6 via activation of the ERK-MAPK pathway promotes 
cell migration in MEFs. We showed that an unphosphorylation mimetic of HDAC6 
serine-1035 site reduces migration possibly due to diminished deacetylation of its 
cytoplasmic substrates α-tubulin. We also showed that HDAC6 may also promote 
cell migration via deacetylation of β-catenin. Finally, we demonstrated that 
HDAC6 promotes cell migration of human cancer cells in vivo. 
Activated ERK-MAPK pathway is involved in promoting cell migration via 
phosphorylation of downstream targets in both the nucleus and cytoplasm (30, 
31). In the cytoplasm, ERK1/2 phosphorylates MLCK which then phosphorylates 
myosin light chain (MLC) leading to cytoskeleton contraction involved in cell 
movement, independent of ERK1/2 entry into the nucleus (31). After we identified 
HDAC6 as a novel target of ERK1, we asked whether phosphorylation of HDAC6 
would affect HDAC6-mediated cell migration. As shown in Fig.1, activation of the 
ERK-MAPK pathway induced cell migration in an HDAC6 dependent manner. 
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Western blotting analyses also indicated activation of the ERK-MAPK pathway. 
These results demonstrated that ERK-MAPK signaling plays a critical role in 
promoting cell migration via HDAC6. It was previously shown that mutationally 
active MAPK ERK kinase (MEK) dramatically increased cell migration by four to 
five folds relative to control cells when Cos-7 cells were used in the experiment 
(31), however, we did not observed a significant effect using active MEK in MEFs 
cells.  
Previous studies have indicated that HDAC6-mediated deacetylation of α-
tubulin promotes cell motility (9, 32). We next used a phosphorylation and 
unphosphorylation mimicking mutant of HDAC6 to perform cell migration studies. 
We observed that unphoshorylation of HDAC6 at the ERK1 phosphorylation site 
significantly decreased migration of cell (Fig. 2). In addition, we observed that 
unphoshorylation of HDAC6 also inhibited deacetylation of α-tubulin in vivo, 
which may explain the inhibited cell migration observed in our studies. Our 
results is also in agreement with other studies that indicated that inhibition of 
HDACs using the pan HDACi trichostatin A and the HDAC6 specific inhibitor 
tubacin leads to hyperacetylated tubulin, resulting in decreased cell motility (14, 
32).  
In our in vivo and in vitro deacetylation experiments, we did not observed 
deacetylation of α-tubulin by the phosphorylation mimicking HDAC6 mutant. 
However, our migration studies indicated that phosphorylation of HDAC6 also 
promotes cell migrations (Fig. 2). We therefore wondered whether additional 
HDAC6 substrates were involved in promoting cell migration. It was previously 
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demonstrated that EGF stimulates HDAC6 dependent deacetylation of β-catenin 
at lysine-49, promoting β-catenin nuclear accumulation and activation of β-
catenin target genes (13). In addition, both hepatocyte growth factor (HGF) and 
EGF induced β-catenin signaling stimulate cell motility. The stabilized form of β-
catenin also showed enhanced migration and the addition of HGF and EGF 
further enhanced migration (18). In a separate study, it was reported that HDAC6 
forms a complex with the cell marker CD133, allowing HDAC6 to deacetylate and 
stabilize β-catenin (21). Furthermore, HDAC6 knock down leads to decreased 
cell proliferation, colony formation, invasion in cell lines, and decreased tumor 
growth in the xenograft model (21). We therefore knocked down β-catenin 
expression using siRNA techniques, and performed migration studies. Our 
results indicated that β-catenin is important in promoting cell migration in HDAC6 
wild type MEFs (Fig. 3). It is possible that HDAC6 deacetylates β-catenin, and 
promote β-catenin activation of its target genes to promote cell migration. One 
well known nuclear target of β-catenin is c-Myc (13, 19), which is involved in 
promoting tumorigenesis (20). We believe that EGF can promote phosphorylation 
of HDAC6, which enhances deacetylation and stabilization of β-catenin to 
promote migration. 
HDAC6 has long been implicated in promoting tumorigenesis (22, 23). 
HDAC6 protein is over expressed in several cancer models and cell lines 
including oral squamous cell carcinoma cell lines, human primary tumor, and in 
human breast cancer tissues (34-36). Our lab has also observed elevated levels 
of HDAC6 protein in human ovarian cancer tissues compared to benign 
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counterparts, and elevated levels of HDAC6 protein in ovarian cancer cell lines 
compared to normal ovarian cell lines (unpublished data). As shown in Fig. 6, a 
similar trend of HDAC6 protein up-regulation is observed in a panel of lung 
cancer cell lines compared to the normal lung cell lines.  
Using H292 lung cancer cell lines, we observed that stable HDAC6 
knockdown significantly impaired both cell migration and cell invasion (Fig. 4B 
and C). Using A549 lung cancer cells, we did not observe a significant difference 
in cell migration or cell invasion between the HDAC6 wild type and HDAC6 knock 
down cells as seen for the H292 cell lines. Other studies using A549 cells in cell 
migration studies also used EGF to stimulate cell migration (38). Since we did not 
used EGF in our study, this could account for why we did not observe a 
significant difference in these cell lines. To complement the cell line migration 
model, we performed tail vein injection of H292 and A549 cells using nude mice. 
We observed the presence of nodules on the lungs, of the mice after six weeks. 
Both cell lines used showed the presence of HDAC6 promoted cell migration in 
vivo compared to the HDAC6 knock down groups. However, the A549 model 
produced a significant difference, whereas, in the H292, group even though a 
difference was observed, it was not as significant owing to the small sample size. 
It is plausible that activation of the ERK-MAPK pathway promotes in vivo 
migration via phosphorylation of HDAC6. It was previously shown that HDAC6-
deficient cells and mice are more resistant to oncogenic Ras-induced 
oncogenesis (22). Our lab previously showed that knock down of HDAC6 
significantly reduced tumor volume and tumor weight in a mouse xenograft 
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model, indicating that HDAC6 is essential in promoting tumor growth (33). We 
also found that reduced tumor growth in HDAC6 knock down cell was due to 
increased basal pro apoptotic signaling, rather than decreased proliferation (33). 
In addition, in cell survival assay, depletion of HDAC6 significantly decreased 
colony formation in H292 cells (33).  
Our data as presented supports HDAC6 role in promoting cell migration 
through deacetylation of its cytoplasmic substrates α-tubulin and β-catenin. We 
also found that phosphorylation of HDAC6 by ERK1 also contributes to HDAC6-
mediated cell migration.  In addition, we found for the first time that HDAC6 
promotes in vivo cell migration using two different human lung cancer cell lines. 
Several studies are using HDACi in combination with other drugs for treatment of 
cancer and other diseased states (6). Our group and others have already shown 
that HDAC6 sensitizes cancer cells to anti-cancer agents (33, 39). Using A549 
cells, it was shown that cells with reduced HDAC6 expression were more 
sensitive to MEK inhibitor, compared to cells expressing HDAC6 (40). In addition, 
MEK inhibitors used in combination with HDACi indicated a lower threshold for 
HDACi. Therefore, based on our results, we identify HDAC6, as well as, ERK1/2, 
as possible targets for future drug designs.  
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Experimental Procedures 
Plasmids, Antibodies, Reagents, and Cell lines 
The hemagglutinin (HA) and flag (F) double tagged HDAC6, HA-HD6-F is 
described in (10). The point mutations on this construct were created by 
QuikChange® XL Site-Directed Mutagenesis Kit (Stratagene). For HA-
HD6(S1035A)-F, the primers used are : 
5’ CCACCAGACCCCCCCAACCGCACCTGTGCAG  3’ and, 
5’  CTGCACAGGTGCGGTTGGGGGGGTCTGGTGG 3’. 
For HA-HD6(S1035D)-F, the primers used are  
5’ CCACCAGACCCCCCCAACCGACCCTGTGCAG  3’ and 
 5’ CTGCACAGGGTCGGTTGGGGGGGTCTGGTGG 3’. The PCR cycle was as 
follows: 95°C, 1 min; followed by 95°C, 50 sec; 60°C , 50 sec; 68°C,  20 min for 
25 cycles and then 68°C, 30 min. 
C-RAF-BXB was described in (41). Anti-HDAC6 (H300) and Total β-
catenin antibodies were purchased from Santa Cruz Biotechnology. Anti-HA 
antibody was purchased from Covance. Anti-acetylated α-tubulin antibody, anti-
β-tubulin antibody and lipofectamine 2000 reagent were purchased from 
Invitrogen.  Anti-Flag antibody and collagen I (#C7661) were purchased from 
Sigma. Anti-ERK1/2 antibody (#9102), anti-phospho-ERK1/2 (Thr202/Tyr204) 
antibody (#9101), β-catenin and control siRNA were purchased from Cell 
Signaling. Luciferin firefly Potassium salt was purchased from Perkin Elmer. 
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HDAC6 wild type and knockout MEFs, were cultured in DMEM medium 
with penicillin (100 U/ml), streptomycin (100 mg/ml) and 10% fetal bovine serum 
(FBS) and incubated at 37ºC with 5% CO2. NSCLC cell lines ADLC, A549, 
EPLC, H292, H460, A460, H522, H2122, H661 and H1299 were obtained from 
the American Type Culture Collection (ATCC). Cells were cultured in RPMI 1640 
medium with penicillin (100 U/ml), streptomycin (100 μg/ml) and 10% fetal bovine 
serum (FBS) and incubated at 37°C with 5% CO2. 
H292 cells were obtained from ATCC and A549-luciferase cells were 
obtained from Moffitt core. Cells were transiently transfected with control vector 
pRS (Cat.# TR20003) or shRNA vector against HDAC6 (recognize sequence 5-
AGGTCTACTGTGGTCGTTACATCAATGGC-3’, tube ID:TI349960, ORIGENE). 
Twenty-four hours after transfection, cells were split to duplicate plates of 1:20 in 
RPMI 1640 medium containing 0.5 μg/ml puromycin. Puromycin was replenished 
every 2 days to maintain sufficient level of selection pressure. The well-isolated 
single clones were transferred into 24-well plates. The knockdown effect was 
verified by Western Blotting analysis using anti-HDAC6 antibodies. 
 
Establishment of stable clones 
To generate the rescue clones in HDAC6 knockout MEFs, empty vector, 
HA-HD6-F, HA-HD6(S1035A)-F and HA-HD6(S1035D)-F were transfected into 
HD6 knockout MEFs using Lipofectamine Plus reagents. One day after 
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transfection, 500 µg/ml G418 was added to the medium to select positive cells. 
Ten days later, stable cell lines were subcloned to 60 mm dishes and 300 µg/ml 
G418 was added to maintain the stable clones. The generated stable clones 
were used in migration experiments. 
Immunoblotting Analysis 
Cells were lysed in LS buffer (PBS [pH 7.5], 10% glycerol, 0.1% NP-40, 
and protease inhibitor cocktail). Protein concentration of all samples was 
determined by Bradford reagent (Bio-Rad). Proteins were resolved on 8%  SDS-
PAGE gels and transferred to nitrocellulose membranes. The membranes were 
probed with primary antibodies and horseradish peroxidase (HRP) conjugated 
secondary antibodies (GE healthcare). The blots were then visualized using 
Chemiluminescent Detection Kit (Pierce). 
 
Cell Migration and Invasion Assay 
First, 24-well transwell migratory cell inserts (8 µm pores, Fisher Scientific) 
were coated with 5 µg collagen 1 and incubated at 4°C overnight.  Before use, 
liquid was aspirated out and the inserts were rinsed with PBS and allowed to dry 
in sterile condition. Cells in serum free medium were seeded into inserts in 
duplicates. 500 µl of medium with 10% FBS was added to the bottom of the well 
and served as an attractant. Cells were allowed to migrate through the inserts for 
indicated times in the figure legend, cells that did not migrate were removed with 
a cotton swab and migratory cells were fixed with 4% paraformaldehyde and 
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stained with crystal violet in ethanol.  Snapshots were taken of the migratory 
cells, then cells were destained in 2% SDS and absorbances were read at 560 
nm. For cell invasion assay, the transwell inserts were coated with matrigel 
instead of collagen, and the same procedures as the migration assay were 
followed. 
 
In Vivo Migration Experiment 
All procedures with mice were approved by an Institutional Animal Care 
and Use Committee (IACUC) in the Division of Research Integrity and 
Compliance at the University of South Florida (Protocol #R4064). The 6 week-old 
female athymic nude mice weighing ~20 g were purchased from the National 
Cancer Institute (NCI). A549-Luciferase and H292 human lung cancer cell lines 
representing control and HDAC6 knock down cells (5×106 cells/200 µl in PBS) 
were injected via tail vein into the mice. For H292 groups cells were allowed to 
grow for six weeks. For A549-luciferase group, mice were injected weekly via 
intraperitoneal with luciferin (from Caliper/Xenogen) in order to visualize the cells 
using bioluminescence imaging. At the end of the six weeks period lungs from 
mice were collected, and macroscopic analyses were perform for the presence of 
nodules. 
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Statistical Analysis 
Results obtained from independent studies are shown with mean ± 
Standard deviation. Statistical analysis was performed using the student’s t-test. 
p-value less than 0.05 was considered significant. 
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FIGURES 
 
 
Figure.4.1. Active Raf Promotes Cell Migration via HDAC6. c-RAF-BXB 
plasmid was transfected into HDAC6 WT or KO MEFs. 40, 000 cells were 
seeded into each inserts to perform the cell migration assays as described in the 
Methods section. Cells were allowed to migrat for 24 hrs. Snapshots of the 
migratory cells were shown as indicated. (B) The stained migratory cells were de-
stained in 2% SDS and then quantified using a spectrophotometer at OD 560 
nm. (C) Anti-P-ERK, anti-T-ERK, anti-mHDAC6, and anti-β-tubulin western blot 
analyses were performed using the cell lines described in (A) and (B). NS stands 
for not significant. ** indicates the p<0.001 
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Figure.4.2. Seine-1035A Mutant of HDAC6 Exerts Decreased Migration 
Potential in MEFs. (A) Cell migration assays were carried out using HDAC6 KO 
MEFs cells stably expressing empty vector, HA-HD6-F, HA-HD6(S1035A)-F or 
HA-HD6(S1035D)-F. 40, 000 cells were seeded into each inserts to perform the 
cell migration assays as described in the Methods section. (A) Cells were 
allowed to migrate for 24 hrs. The snapshots of the migratory cells were shown 
as indicated. (B) The stained migratory cells were de-stained in 2% SDS and 
then quantified at OD 560 nm. NS stands for not significant. * indicates the 
p<0.01.  (C) Anti-HDAC6 and anti-α-tubulin Western blot analyses were 
performed using the cell lines described in (A) and (B).  
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Figure.4.3. β-Catenin Knock Down Reduces Cell Migration in MEFs Cells. β-
catenin was knocked down in HDAC6 WT MEFs cells before performing the 
migration assay as described in the Methods section. 200, 000 cells were seeded 
into each inserts, and cells were allowed to migrate for 6 hrs. The snapshots of 
the migratory cells were shown as indicated (A). (B) The stained migratory cells 
were de-stained in 2% SDS and then quantified at OD 560 nm. (C) Anti-total β-
catenin, anti-mHDAC6 and anti-β-actin Western blot analyses were performed 
using β-catenin knock down cells as used for the migration studies. 
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Figure.4.4. HDAC6 Promotes Migration and Invasion in H292 Cell Lines, and 
In Vivo Migration in a Mouse Model. (A), H292 cells were transfected with 
control shRNA or shRNA against HDAC6 to generate stable clones. HDAC6 
expression was detected by western blotting analysis using anti-HDAC6 
antibody. Acetylated α-tubulin serves as control for HDAC6 deacetylase activity. 
β-actin was used to ensure equal loading of protein. Cell migration and invasion 
assays were carried out using H292 HDAC6 control (pRS) and HDAC6 
knockdown (HD6KD) cells. 100, 000 cells were seeded into each inserts to 
perform the cell migration assays as described in the Methods section. Cells 
were allowed to migration or invade on collagen 1 or matrigel matrix for 24 hrs. 
(B) snapshots of the migratory cells and (C) snapshots of invaded cells are 
shown as indicated. Mice injected with H292 pRS or H292-HD6 were weighed 
weekly for 6 weeks, and differences were plotted as shown in (D). Macroscopic 
analysis of nodules on the lungs of mice injected via tail vein with H292 HD6-pRS 
or H292-HD6KD cells, or lungs from normal mice that was not injected with cells 
(E). Scatter plot indicates the number of nodules counted on the surface of the 
lungs during macroscopic analysis (F). 
FE
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Figure.4.5. HDAC6 Promotes In Vivo Migration of Human A549 Cell in a 
Mouse Model. (A), A549 cells expressing firefly Luciferase genes were 
transfected with control shRNA or shRNA against HDAC6 to generate stable 
clones. HDAC6 expression was detected by western blotting analysis using anti-
HDAC6 antibody. Acetylated α-tubulin serves as control for HDAC6 deacetylase 
activity. β-actin was used to ensure equal loading of protein. B, Ex vivo imaging 
of mice preformed on Day of injection (Day 0), indicating a successful injection of 
luciferase expressing A549 cells. Mice injected with A549 pRS-Luc or A549-
HD6KD-Luc cells were weighed weekly for 6 weeks, and differences were plotted 
as shown in (C). Macroscopic analysis of nodules on the lungs of mice injected 
via tail vein with A549 HD6-pRS-Luc or A549-HD6KD-Luc cells, or lungs from 
normal mice that was not injected with cells (D). Scatter plot indicates the 
number of nodules counted on the surface of the lungs during macroscopic 
analysis (E). 
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Figure.4.6. HDAC6 Expression is Up-Regulated in Lung Cancer Cell Lines 
Compared to the Normal Lung Cell Lines. Total protein extracts were 
prepared from two normal lung cell lines (LL24 and HBE4), and several lung 
cancer cell lines (ADLC, EPLC, H2172, H522, A549, H2122, H661, H460, A460, 
H1299, and H292). Protein extracts were analyzed by western blotting analyses. 
* indicates cell lines with a K-Ras mutation.  
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CHAPTER FIVE 
DISCUSSION 
 
Overview 
Acetylation and deacetylation are post translational modifications that 
occur on the ε-amino group of lysine residues (1). Histone acetyltransferases 
(HATs) and histone deacetylases (HDACs) catalyze this reversible reaction (1, 
2).  Histones were initially identified as substrates for HATs and HDACs, but it 
later became apparent that numerous nonhistone proteins were also able to 
undergo reversible acetylation (2, 3). In fact, several cellular processes such as 
transcription, translation, DNA repair, and metabolism are regulated in part by the 
actions of HATs and HDACs (2, 4). 
There are 18 identified human HDACs family members group together into 
four families depending on their sequence similarity and cofactor dependency 
(2). Because of the different cellular processes affected by the HDACs, 
divergence in their role can lead to disease states including cancer (2). In 
addition, cellular processes including promotion of cellular proliferation, 
metastasis, angiogenesis, apoptosis prevention and differenciation are all 
hallmarks of cancer (5). Interestingly, many of the HDAC family members are 
involved in promoting these processes (4, 5).  
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Histone deacetylase 6 (HDAC6), is also involved in promoting cancer by 
affecting cell proliferation, angiogeneisis, cell migration and metastasis (5-8).  
HDAC6 promotes cells motility through its ability to deacetylate its cytoplasmic 
substrates α-tubulin and cortactin, thereby affecting both the microtubule and 
actin network (6, 8). HDAC6 is also required for efficient oncogenic 
transformation and tumor formation (9). In addition, HDAC6 expression is up-
regulated in many different cancer tissues compared to their non cancerous 
counterparts. HDAC6 is up-regulated in oral squamous cell carcinoma (10), 
ovarian cancer tissues and cell lines (unpublished data), and in breast cancer 
tissues (11).  However, in contrast to the other tumor types, HDAC6 may serve 
as a biomarker for endocrine responsiveness in patients with breast cancer. 
Higher HDAC6 mRNA was detected in patients with smaller tumors and lower 
histological grade, and in estrogen receptor α and progesterone receptor positive 
tumors (11). Patients expressing higher levels of HDAC6 mRNA were found to 
be more responsive to endocrine treatment compared to those with low levels 
(11). Therefore, understanding the mechanisms through which HDAC6 promotes 
its function, as well as understanding how different cellular pathways affect 
HDAC6 roles in promoting tumorigenesis may prove beneficial.  
 
ERK1 Phosphorylates HDAC6 to Promote Cell Migration 
The extracellular signal regulated kinase (ERK)-MAPK pathway is a 
phosphorylation cascade that regulates many cellular processes within the cell 
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(12). Growth factors such as epidermal growth factor (EGF) activate the pathway 
by binding to their respective receptor, in this case EGFR. Binding of growth 
factors to receptors lead to phosphorylation and activation of Ras-RAF-MEK1/2 
and ERK1/2 (12). ERK1 and ERK2 have numerous substrates both in the 
cytoplasm and the nucleus. And through these substrates, ERK1/2 promote their 
functions (12).  
We have discovered that ERK-MAPK pathway activation leads to HDAC6 
phosphorylation and HDAC6-mediated cell migration. Using mass spectrometric 
analysis, we identified serine-1035 within the c-terminal region of HDAC6 as a 
phosphorylation site. In addition, we also found that serine-1035 is located within 
the extracellular signal regulated kinase (ERK) recognition motif (13). We 
showed that ERK1 phosphorylates HDAC6 both in vitro and in vivo using 
bacterial expressed HDAC6 proteins, the MEK inhibitors U0126 and PD98059, 
and an unphosphorylation and phosphorylation mimicking mutants of HDAC6 
serine-1035 site. For the mimicking mutants, HDAC6 amino acid serine-1035 
was mutated to alanine or aspartic acid to mimic an unphosphorylation or 
phosphoryation form of HDAC6, respectively. We also used active Ras and MEK, 
and dominant-negative MEK to show that activation of the EGFR-Ras-Raf-MEK-
ERK signaling axis leads to phosphorylation of HDAC6 at its serine-1035 site. 
Secondly, we investigated how ERK1-mediated HDAC6 phosphorylation 
affects HDAC6 deacetylase function in regards to its substrates. Using the 
unphosphorylation and phosphorylation mimicking mutants of HDAC6 serine-
1035 site, we determined that modification at this site does not affect HDAC6’s 
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ability to deacetylate core histones. It was previous shown that HDAC6 
deacetylate the F-actin associated protein cortactin, to promote cell motility (8). 
ERK1/2 also phosphorylates cortactin and promotes cortactin localization to sites 
of dynamic actin assembly in tumor cells. Whereas, inhibiting ERK1/2 
phosphorylation result in decreased lamellipodia persistence, which is necessary 
for cell movement (14). We did not observe any differences in the 
unphosphorylation or phosphorylation mimetics of HDAC6 to deacetylate 
cortactin compared to HDAC6 wild type. 
Microtubules are components of the cytoskeleton network (15). They are 
highly dynamic polymers made up of α/β tubulin heterodimers (15). α-tubulin is 
another HDAC6 cytoplasmic substrate involved in promoting cell motility (6, 16). 
Other phosphorylation sites within HDAC6 structure affect HDAC6’s ability to 
deacetylate α-tubulin differently, resulting in either enhanced or reduced function 
of α-tubulin (17-19). Glycogen synthase kinase 3β (GSK-3β) phosphorylates 
HDAC6 at serine-22 in its N-terminal region, enhancing deacetylation of α-tubulin 
(17). Deacetylation of α-tubulin decreases its stability and results in decrease 
mitochondrial motility and transport of other kinesin-1 dependent cargo (17). The 
centrosomal kinase Aurora A also phosphorylates HDAC6 at an undetermined 
site (19). Aurora A phosphorylation of HDAC6 stimulates HDAC6 deacetylase 
activity towards α-tubulin, and leads to reduced ciliary resorption (19). Epidermal 
growth factor receptor (EGFR) kinase also phosphorylates HDAC6 on its 
tyrosine-570 residue (18). EGFR kinase phosphorylation of HDAC6 reduces 
HDAC6 deacetylase activity towards α-tubulin, thus increasing a more stable 
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form of acetylated α-tubulin and enhancing cargo transport (18). In our in vivo 
studies, we found that mutation of HDAC6 at serine-1035 to either the 
unphosphorylation or phosphorylation mimetics reduces HDAC6 ability to 
deacetylate α-tubulin. Unphosphorylation of HDAC6 at serine-1035 inhibits 
deacetylation of α-tubulin and showed reduced cell migration. In other studies 
inhibiting deacetylation of α-tubulin using HDACs inhibitor was also shown to be 
associated with reduced cell motility (6, 16).  
β-catenin is also a cytoplasmic substrate of HDAC6 (20). EGF stimulates 
HDAC6 relocalization to the cell membrane, where HDAC6 associates with and 
deacetylates β-catenin leading to β-catenin stabilization (20). Stabilized β-catenin 
then enters the nucleus where it activates target genes such as c-Myc (20). 
Although HDAC6 is involved in β-catenin mediated cell migration through a 
complex with cell surface marker CD133, the exact mechanism remains unclear 
(21). After we found that EGF leads to activation of the ERK-MAPK pathway, and 
HDAC6 phosphorylation, we questioned whether ERK-mediated phosphorylation 
of HDAC6 enhances deacetylation of β-catenin. Using HDAC6 unphosphorylated 
and phosphorylated mimetics, we determined that the phosphorylation mimicking 
mutant of HDAC6 enhanced deacetylation of β-catenin similar to that of HDAC6 
wild type. We further performed transwell migration studies by first knocking 
down β-catenin using siRNA techniques in HDAC6 expressing MEFs. We 
observed reduced migration of cells in the β-catenin knock down group 
compared to the control siRNA group. Therefore, it is possible that HDAC6 
promotes cell migration through deacetylation of β-catenin.  
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HDAC6 Promotes In Vivo Cell Migration 
Cell migration and tumor metastasis are processes of epithelial 
mesenchymal transition (22). Tumor cells acquire motile characteristics through 
activation or repression of transcription factors. Tumor cells are then able to gain 
access to the blood stream or lymph nodes and travel to other sites within the 
body (22). Cells that survive, extravasate into surrounding tissues where they 
initiate new tumor growth (22). HDAC6 is required for efficient oncogenic 
transformation and tumor formation (9). Our group has also shown that depleting 
HDAC6 in human lung cancer cell line H292 decreases tumor weight and tumor 
volume in a xenograft model (23). HDAC6 is well known to promote cell migration 
in cell line models (6, 8), but whether this is true in vivo has not been shown. Cell 
migration in vitro is thought to be a reflection of cellular function in tumor 
formation and metastasis in vivo. In this study, we used the tail vein injection 
method to show for the first time that HDAC6 promotes migration of human lung 
cancer cell in vivo. We used macroscopic analysis to determine the number of 
nodules on the surface of the lung of athymic nude mice following a six weeks 
period. In the HDAC6 expressing cells we observed a significant increase 
(p<0.045) in the number of nodules compared to the HDAC6 deficient 
counterparts in A549 human lung cancer cell lines. We also observed a non 
significant increase in the number of nodules in the presence of HDAC6 when 
H292 human lung cancer cells were used. However, we believe that the non 
significant increase seen in the H292 group was due to the small sample size 
used in this study. In both cases, we did not observe any nodules on the 
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surrounding tissues and organs. Further analysis on the collected lung sample 
will be used to determine protein expression in the HDAC6 expressing verses the 
HDAC6 deficient groups. Interestingly, in another study, A549 cells injected 
directly into the liver of mice resulted in wide spread metastasis to the lung, 
spleens and lymph node by week 6 and 7 (24). In addition, the group that 
performed this study used twice as many cells in their experiment, which may 
account for the widespread metastasis (24). Overall, we have provided results in 
support of HDAC6 mediated migration in vivo.  
 
Considering HDAC Inhibitors as Novel Therapeutic Agents 
Histone deacetylase inhibitors (HDACi) have been the focus of many 
research efforts, either alone or in combination with other drug treatments (25). 
Overall, HDACi in combination with other drugs have shown some promising 
results (25). Depletion of HDAC6 in non-small cell lung cancer cell lines 
sensitizes cells to cisplatin treatment (23). HDACi or down-regulation of HDAC1 
and HDAC6 using shRNA techniques enhances cytarabine-induced apoptosis in 
pediatric acute myeloid leukemia cells (26). Tubacin is an HDAC6 specific 
inhibitor (16). The used of tubacin showed higher antiproliferative effect and 
apoptosis induction in acute lymphoblastic leukemia (ALL). In addition, tubacin 
enhances the effect of chemotherapy for treatment of primary ALL both in vitro 
and in vivo (27). Finally, inhibiting HDAC6 using tubacin, enhances cell death 
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induced by the topoisomerase II inhibitors etoposide and doxorubicin, and the 
HDACi vorinostat (28).  
Other associated proteins uncovered in this study also serves as a 
suitable therapeutic targets as well. The ERK-MAPK pathway promotes 
tumorigenesis via upstream activating mutations within the pathway (29, 30). The 
ERK-MAPK pathway activation promotes cell migration, metastasis, apoptosis 
and angiogenesis (29, 30). ERK 1/2 also phosphorylates several proteins that 
promote cell migration. These proteins include myosin light chain kinase, calpain, 
focal adhesion kinase and paxillin (31). These proteins also regulate the 
dynamics of focal adhesion, reorganization of microtubules and filamentous 
actin, cell spreading and lamellipodium extension involve in cell movement (31). 
ERK 1/2 are also up-regulated in HDAC6 deficient lung cancer cell lines, and 
these cell types were also shown to be more sensitive to MEK inhibitors 
compared to cells expressing HDAC6 (32). HDAC6 cytoplasmic substrate β-
catenin, is up-regulated in many cancer types including cancer of the colon, lung 
and breast (33). Interestingly, the convergence of the canonical Wnt pathway 
through β-catenin, and the ERK-MAPK pathway through EGF and EGFR 
activation is already documented (20, 34). Therefore, HDAC6 specific inhibitor in 
combination with an ERK1/2 inhibitor appears to be an effective therapeutic 
agent.  
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Significance of this Study 
 HDAC6 promotes cell motility through deacetylation of its cytoplasmic 
substrates α-tubulin, and cortactin, thereby affecting the microtubule and the 
actin network (6, 8). HDAC6 expression is up-regulated in many different cancer 
tissues compared to their normal tissue counterpart (10, 11), and animal models 
implicate HDAC6 in tumorigenesis (9). Understanding the mechanisms through 
which HDAC6 promotes cell motility and metastasis will be beneficial for 
designing HDAC6 specific inhibitors. We have identified serine-1035 as a novel 
phosphorylation site of HDAC6, and ERK1 as the kinase targeting this site. We 
showed that phosphorylation of HDAC6 at the serine-1035 site facilitates 
HDAC6-mediated cell migration through its cytoplasmic substrates α-tubulin and 
β-catenin. Because ERK1/2 also promotes tumorigenesis through activating 
mutations (29), inhibitors of the ERK-MAPK pathway are also the focus of many 
research efforts. It is plausible that both HDAC6 specific inhibitors and ERK1/2 
inhibitors combination can be beneficial for cancer treatments. 
 
Limitations and Future Studies 
 To prove that ERK1 phosphorylates HDAC6, we used a series of MEK 
inhibitors, active and dominant-negative kinases, and unphosphorylation and 
phosphorylation mimetics of HDAC6. However, during the preparation of this 
dissertation we were able to obtain preliminary data on the phospho site specific 
antibody of HDAC6 (p-S1035). In the presence of EGF treatment, HDAC6 
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phosphorylation level was increased compared to the non-EGF treatment group. 
HDAC6 phosphorylation in the presence of EGF was concurrent with an increase 
in ERK1/2 phosphorylation downstream. Overall, generation of the site specific 
antibody and further optimization will give us the ability to detect whether ERK-
mediated phosphorylation of HDAC6 is also up-regulated in cancer patient’s 
tissue samples. In the in vivo migration model, we used tail vein injection. This 
procedure allows, a rapid time course. In this model, early stages in the 
metastatic cascade such as cell invasion into surrounding tissues, and 
intravasation into the blood stream were eliminated. In the tail vein models, cells 
usually circulate in high number, and it is unlikely that they will interact with the 
target tissue in the same way as spontaneous metastasizing cells. As such, 
different metastasizing cells may have a different genetic profile (35). 
 HDAC6 was shown to affect other cellular processes involved in the EMT 
process including angiogenesis and cellular adhesion (7, 36). It will be interesting 
to determine how ERK1-mediated HDAC6 phosphorylation affects these 
processes as well. Future projects are aimed at deciphering the role of HDAC6 in 
these processes. Obtaining the site specific antibody may also prove to be 
beneficial. Previously, we used the unphosphorylation and phosphorylation 
mimicking mutants and mass spectrometric analysis to identify any additional 
interacting protein of HDAC6, however, this technique was unsuccessful. With 
the use of the site specific antibody we hope to determine whether 
phosphorylated HDAC6 localization differs from HDAC6 wild type and whether 
there are additional proteins that interact with HDAC6 to promote cell migration.  
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